EP1066295A2 - Synthesis of compounds and libraries of compounds - Google Patents
Synthesis of compounds and libraries of compoundsInfo
- Publication number
- EP1066295A2 EP1066295A2 EP99912805A EP99912805A EP1066295A2 EP 1066295 A2 EP1066295 A2 EP 1066295A2 EP 99912805 A EP99912805 A EP 99912805A EP 99912805 A EP99912805 A EP 99912805A EP 1066295 A2 EP1066295 A2 EP 1066295A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- group
- library
- carboxyl
- compounds
- methylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 229
- 238000003786 synthesis reaction Methods 0.000 title abstract description 46
- 230000015572 biosynthetic process Effects 0.000 title abstract description 43
- 239000000178 monomer Substances 0.000 claims abstract description 172
- 238000000034 method Methods 0.000 claims abstract description 91
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 74
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 66
- 239000000816 peptidomimetic Substances 0.000 claims abstract description 46
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 23
- 239000002243 precursor Substances 0.000 claims abstract description 11
- -1 vinyl halide Chemical group 0.000 claims description 154
- 238000006243 chemical reaction Methods 0.000 claims description 117
- 125000003118 aryl group Chemical group 0.000 claims description 88
- 239000001257 hydrogen Substances 0.000 claims description 82
- 229910052739 hydrogen Inorganic materials 0.000 claims description 82
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 82
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 81
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 74
- 150000001336 alkenes Chemical group 0.000 claims description 61
- 125000001072 heteroaryl group Chemical group 0.000 claims description 59
- 150000001412 amines Chemical group 0.000 claims description 47
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 47
- 150000001345 alkine derivatives Chemical group 0.000 claims description 45
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 43
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 43
- 125000000217 alkyl group Chemical group 0.000 claims description 42
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 42
- 150000004820 halides Chemical class 0.000 claims description 42
- 229920002554 vinyl polymer Polymers 0.000 claims description 41
- 125000004104 aryloxy group Chemical group 0.000 claims description 40
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims description 40
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 40
- 125000006239 protecting group Chemical group 0.000 claims description 40
- 239000007787 solid Substances 0.000 claims description 40
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 39
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 38
- 229910052799 carbon Inorganic materials 0.000 claims description 38
- 229910052757 nitrogen Inorganic materials 0.000 claims description 37
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 36
- 229920000642 polymer Polymers 0.000 claims description 35
- 229910052760 oxygen Inorganic materials 0.000 claims description 29
- 239000001301 oxygen Substances 0.000 claims description 29
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 26
- 229910052717 sulfur Inorganic materials 0.000 claims description 24
- 150000001408 amides Chemical class 0.000 claims description 23
- 125000005647 linker group Chemical group 0.000 claims description 21
- 239000011593 sulfur Substances 0.000 claims description 21
- 229910019142 PO4 Inorganic materials 0.000 claims description 18
- 235000021317 phosphate Nutrition 0.000 claims description 18
- 150000004657 carbamic acid derivatives Chemical class 0.000 claims description 17
- 235000013877 carbamide Nutrition 0.000 claims description 17
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 17
- LIKFHECYJZWXFJ-UHFFFAOYSA-N dimethyldichlorosilane Chemical compound C[Si](C)(Cl)Cl LIKFHECYJZWXFJ-UHFFFAOYSA-N 0.000 claims description 17
- 150000002019 disulfides Chemical class 0.000 claims description 17
- 150000002905 orthoesters Chemical class 0.000 claims description 17
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 17
- 150000003672 ureas Chemical class 0.000 claims description 17
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 14
- 229910052796 boron Inorganic materials 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 14
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims description 14
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical group [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 13
- 125000000524 functional group Chemical group 0.000 claims description 13
- 229910052719 titanium Inorganic materials 0.000 claims description 13
- SKCDNIBJOGKNLZ-UHFFFAOYSA-N n-[amino(chloro)phosphanyl]oxy-n-propan-2-ylpropan-2-amine Chemical compound CC(C)N(C(C)C)OP(N)Cl SKCDNIBJOGKNLZ-UHFFFAOYSA-N 0.000 claims description 10
- 238000006352 cycloaddition reaction Methods 0.000 claims description 9
- 238000005906 dihydroxylation reaction Methods 0.000 claims description 9
- 238000006735 epoxidation reaction Methods 0.000 claims description 9
- 238000005984 hydrogenation reaction Methods 0.000 claims description 9
- 238000005865 alkene metathesis reaction Methods 0.000 claims description 6
- 238000007242 hydrozirconation reaction Methods 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 5
- 238000010532 solid phase synthesis reaction Methods 0.000 claims description 5
- 230000000707 stereoselective effect Effects 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 claims description 3
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 claims description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 3
- 125000005842 heteroatom Chemical group 0.000 claims description 3
- 125000004434 sulfur atom Chemical group 0.000 claims description 3
- 150000003573 thiols Chemical class 0.000 claims description 3
- 108091008023 transcriptional regulators Proteins 0.000 claims description 3
- 108020001738 DNA Glycosylase Proteins 0.000 claims description 2
- 102000028381 DNA glycosylase Human genes 0.000 claims description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 34
- 150000007970 thio esters Chemical class 0.000 claims 18
- 150000002148 esters Chemical class 0.000 claims 17
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 claims 13
- 125000004430 oxygen atom Chemical group O* 0.000 claims 10
- 238000005888 cyclopropanation reaction Methods 0.000 claims 8
- IDNJBJJSMDYULP-UHFFFAOYSA-N chlorophosphonamidous acid Chemical compound NP(O)Cl IDNJBJJSMDYULP-UHFFFAOYSA-N 0.000 claims 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 2
- 150000001298 alcohols Chemical class 0.000 claims 2
- 150000004808 allyl alcohols Chemical class 0.000 claims 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 claims 2
- QEWLAXQBHYLUSH-VGMNWLOBSA-N (2s)-1-[(2s,4r)-1-(2-aminoacetyl)-4-hydroxypyrrolidine-2-carbonyl]pyrrolidine-2-carboxylic acid Chemical group NCC(=O)N1C[C@H](O)C[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 QEWLAXQBHYLUSH-VGMNWLOBSA-N 0.000 claims 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 claims 1
- LCKIEQZJEYYRIY-UHFFFAOYSA-N Titanium ion Chemical compound [Ti+4] LCKIEQZJEYYRIY-UHFFFAOYSA-N 0.000 claims 1
- CKUAXEQHGKSLHN-UHFFFAOYSA-N [C].[N] Chemical compound [C].[N] CKUAXEQHGKSLHN-UHFFFAOYSA-N 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 12
- 230000003278 mimic effect Effects 0.000 abstract description 5
- 230000003993 interaction Effects 0.000 abstract description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 51
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 40
- 239000000243 solution Substances 0.000 description 35
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 31
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 24
- 235000019439 ethyl acetate Nutrition 0.000 description 20
- 239000000047 product Substances 0.000 description 16
- 238000003756 stirring Methods 0.000 description 14
- 239000007790 solid phase Substances 0.000 description 13
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 12
- 239000012043 crude product Substances 0.000 description 10
- 238000003818 flash chromatography Methods 0.000 description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 239000003054 catalyst Substances 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 150000001299 aldehydes Chemical group 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 229910052723 transition metal Inorganic materials 0.000 description 6
- 150000003624 transition metals Chemical class 0.000 description 6
- 238000006969 Curtius rearrangement reaction Methods 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000007306 functionalization reaction Methods 0.000 description 5
- 238000006046 pinacol coupling reaction Methods 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 229910001868 water Inorganic materials 0.000 description 5
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 4
- HSJKGGMUJITCBW-UHFFFAOYSA-N 3-hydroxybutanal Chemical compound CC(O)CC=O HSJKGGMUJITCBW-UHFFFAOYSA-N 0.000 description 4
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical group [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- 150000001241 acetals Chemical class 0.000 description 4
- 229940125758 compound 15 Drugs 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 4
- 238000005649 metathesis reaction Methods 0.000 description 4
- 238000005935 nucleophilic addition reaction Methods 0.000 description 4
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 4
- 229960000395 phenylpropanolamine Drugs 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 3
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 3
- 229940126657 Compound 17 Drugs 0.000 description 3
- RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 3
- 238000005575 aldol reaction Methods 0.000 description 3
- PNPBGYBHLCEVMK-UHFFFAOYSA-L benzylidene(dichloro)ruthenium;tricyclohexylphosphane Chemical compound Cl[Ru](Cl)=CC1=CC=CC=C1.C1CCCCC1P(C1CCCCC1)C1CCCCC1.C1CCCCC1P(C1CCCCC1)C1CCCCC1 PNPBGYBHLCEVMK-UHFFFAOYSA-L 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229940125797 compound 12 Drugs 0.000 description 3
- 229940126543 compound 14 Drugs 0.000 description 3
- 229940126142 compound 16 Drugs 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 238000006880 cross-coupling reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000010936 titanium Substances 0.000 description 3
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- SVWCVXFHTHCJJB-UHFFFAOYSA-N 4-methylpentanoyl chloride Chemical compound CC(C)CCC(Cl)=O SVWCVXFHTHCJJB-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical group OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 238000006644 Lossen rearrangement reaction Methods 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 238000006405 Nozaki-Hiyama-Kishi reaction Methods 0.000 description 2
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 2
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 2
- 238000006923 Schmidt rearrangement reaction Methods 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- UENWRTRMUIOCKN-UHFFFAOYSA-N benzyl thiol Chemical compound SCC1=CC=CC=C1 UENWRTRMUIOCKN-UHFFFAOYSA-N 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012039 electrophile Substances 0.000 description 2
- 238000005187 foaming Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000012038 nucleophile Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 238000006303 photolysis reaction Methods 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000010916 retrosynthetic analysis Methods 0.000 description 2
- 238000006798 ring closing metathesis reaction Methods 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- XXSCONYSQQLHTH-UHFFFAOYSA-N 9h-fluoren-9-ylmethanol Chemical compound C1=CC=C2C(CO)C3=CC=CC=C3C2=C1 XXSCONYSQQLHTH-UHFFFAOYSA-N 0.000 description 1
- 241000252095 Congridae Species 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 1
- 108700034637 EC 3.2.-.- Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 238000007341 Heck reaction Methods 0.000 description 1
- 238000007167 Hofmann rearrangement reaction Methods 0.000 description 1
- 101000772888 Homo sapiens Ubiquitin-protein ligase E3A Proteins 0.000 description 1
- NUGPIZCTELGDOS-QHCPKHFHSA-N N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclopentanecarboxamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CC[C@@H](C=1C=NC=CC=1)NC(=O)C1CCCC1)C NUGPIZCTELGDOS-QHCPKHFHSA-N 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000014400 SH2 domains Human genes 0.000 description 1
- 108050003452 SH2 domains Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 229910003074 TiCl4 Inorganic materials 0.000 description 1
- 102100030434 Ubiquitin-protein ligase E3A Human genes 0.000 description 1
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 150000001335 aliphatic alkanes Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- WMHOESUUCMEQMS-UHFFFAOYSA-L bis[(2,2,2-trifluoroacetyl)oxy]mercury Chemical compound [Hg+2].[O-]C(=O)C(F)(F)F.[O-]C(=O)C(F)(F)F WMHOESUUCMEQMS-UHFFFAOYSA-L 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 125000005026 carboxyaryl group Chemical group 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008568 cell cell communication Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000005686 cross metathesis reaction Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- FAVAVMFXAKZTMV-UHFFFAOYSA-N dibutylboranyl trifluoromethanesulfonate Chemical compound CCCCB(CCCC)OS(=O)(=O)C(F)(F)F FAVAVMFXAKZTMV-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical group [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000006525 intracellular process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000003541 multi-stage reaction Methods 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- IYGKNJSTHXRTOV-UHFFFAOYSA-N phenoxymethyl hypobromite Chemical group BrOCOC1=CC=CC=C1 IYGKNJSTHXRTOV-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000005541 phosphonamide group Chemical group 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000015843 photosynthesis, light reaction Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 238000005872 self-metathesis reaction Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000000526 short-path distillation Methods 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 1
- 230000006648 viral gene expression Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/08—Oxygen atoms
- C07D223/10—Oxygen atoms attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/11—Compounds covalently bound to a solid support
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
Definitions
- Figure 6 depicts bond construction through tandem aldol reaction followed by Curtius rearrangement
- Figure 7 depicts hydrozirconation reactions
- Figure 8 depicts a nucleophihc addition reaction
- Figure 13 depicts a convergent and efficient synthesis of monomers
- Figure 14 depicts Hoffman, Lossen and Schmidt Rearrangements
- Figure 17 depicts reaction of a dusopropyl amino chlorophosphoramidite linker with preferred monomers of the invention
- Figure 19 depicts separation of two libraries generated from intermolecular olefin cross metathesis
- Figuie 20 depicts bond construction through cycJoaddition Figure 21 depicts a diversifiable core structure from the thesis of Ann Weber
- Figure 28 depicts a library of synthetic transcriptional regulators
- Figure 30 depicts a use for the compounds and libraries of the present invention in the remn-angiotensin system
- peptidomimetic refers to a chemical compound that, at least in part, mimics one or more structural or functional properties of a peptide
- the prior art definition of peptidomimetic focuses on compounds in which one or more of the characteristic chemical moieties of a peptide is substituted with alternative functional groups.
- the present invention provides a broader concept of peptidomimetic, describing a system for producing a wide variety of chemical compounds that may have one or more structural or functional aspects of biologically active peptides.
- Combinatorial Library refers to a collection of compounds produced in a manner that allows “segment units”, 'functionality units”, “monomer units”, “biomolecule units”., or any combination thereof, to be varied in a systematic fashion.
- the segment unit may be generated from any compatible reaction between monomers (or upon a monomer) that results in a replacement of the amide functionality with any other functionality.
- the functionality units may be varied on individual monomers, or after monomers have been joined together. These functionality units may be present within the segment unit of the joined monomers, or may be present at other sites within the monomers.
- “Monomer unit” refers in one aspect to a molecule that can be joined together to form another molecule or set of molecules, such as a set of oligomers or polymers.
- “monomer unit”, as used herein, refers to a molecule that can be diversified at particular sites on the monomer unit. More particularly, the present invention refers to a monomer that is characterized in that it contains reactive moieties available for diversification and optionally is characterized by the presence of a reactive moiety that allows linkage of multiple individual monomers by way of a segment unit functionality
- Enantiomer refers to a stereoisomer that is related to another stereoisomer as an object and its mirror image
- Diastereomer refers to a stereoisomer that is related to another stereoisomer in a manner other than as an object and its mirror image For example, one stereogenic center relative to another stereogenic center is different for diastereomers Diastereomers differ from one another both in phvsical properties and in chemical reactivities For example, different diasteriomers generally have different melting points, boiling points, and solubility characteristics
- stereoselective reaction refers to a chemical reaction in which one of the stereoisome ⁇ c products is formed in excess
- Enantioselective Reaction refers to a chemical reaction in which one of the enantiome ⁇ c products is formed in excess
- Diastereoselective reaction refers to a reaction in which only one of the diastereome ⁇ c products is formed in excess, or one m which the major product is diastereome ⁇ cally pure
- the present invention provides methods and compounds related to production of complex libraries of chemical compounds with certain structural and/or functional characteristics of peptides.
- the present invention in a broader aspect, provides for the generation of chemical libraries of peptidomimetics and non- peptidomimetics alike, having stereoisomerism as a diversity element.
- the inventive reactions involve steps of (1) providing at least two monomer compounds, each of which has at least two terminal reactive moieties; and (2) reacting the monomers with one another, under conditions that allow for the control of stereochemistry as well as chemoselectivity, so that they become linked together at one of their reactive moieties and generate a segment unit, and (3) generating diversifiable isolable compounds or libraries of compounds.
- each monomer contains multiple reactive moieties, and additional reactions are performed to functionalize these moieties either before or after the monomers are linked to one another, so that highly complex libraries are produced.
- the inventive reactions involve steps of (1) providing at least one monomer compound, which has at least two terminal reactive moieties; (2) reacting the monomer with a reagent that allows for the control of stereochemistry as well as chemoselectivity, and (3) generating diversifiable isolable compounds or libraries of compounds with characteristics reminiscent of peptides.
- One advantage of the inventive synthetic system is that it allows simultaneous production of a large number of complex peptidomimetic compounds under conditions of controlled stereo- and regio-selectivity.
- Preferred peptidomimetic compounds produced according to the present invention contain both peptide bond and functional group substitutions when compared with peptides.
- the present invention provides methods for the generation of compounds and libraries of compounds, peptidomimetics and non-peptidomimetics alike, having stereochemical diversity
- This method involves the steps of (1) selecting desired synthetic precursors having a predefined stereochemical relationship, (2) reacting the synthetic precursors so that a compound having a specific stereochemistry is obtained, and (3) repeating these steps of selecting and reacting until a desired library of compounds having stereochemical diversity is obtained
- a library of compounds having only diversity of stereochemistry is provided for these embodiments, it is particularly preferred that at least 4 stereoisomers are provided, more particularly preferred that at least 8 stereoisomers are provided, and most particularly preferred that at least 16 stereoisomers are provided
- a library of compounds having structural diversity and stereochemical diversity is provided
- FIG. 2 depicts the retrosynthetic analysis of a preferred diversifiable peptidomimetic core, in which two monomers are used to generate the desired structure.
- Each monomer is characterized either by the presence of a reactive moiety that facilitates the linkage of the monomers to one another by way of a segment unit, or by the presence of a reactive moiety that facilitates the reaction of the monomers with chemical reagents.
- Each monomer preferably also contains additional reactive moieties available for diversification, so that the peptidomimetic compounds produced according to the present invention can be diversified both at the level of the segment unit structure and at the level of functional groups.
- each monomer contains at least one terminal reactive moiety that allows the monomer to be linked to a biomolecule.
- each monomer contains a moiety available for linkage to a peptide, so that the inventive peptidomimetic compounds can readily be embedded within a peptide chain.
- each monomer is selected to react with the other monomer being employed.
- the chemical nature of the moiety on the first monomer that is available for linkage to the second monomer places constraints on the nature of the acceptable second monomer moiety and therefore limits the selection of the second monomer, and also limits the resulting stereoselectivity.
- at least one monomer contains a reactive moiety available for linkage to the solid phase. Such linkage may be direct or indirect.
- the monomer may be linked to another molecule, preferably a biomolecule (and most preferably a peptide) that is itself linked to the solid phase.
- a biomolecule and most preferably a peptide
- Methods of linking compounds to the solid phase are known in the art and a variety of methods may be employed in the present invention. (See, for example, Brown, "Recent Developments in Solid-Phase Organic Synthesis” Contemporary Organic Synthesis, 1997, p 216, Hiroshige et al , Eet lett 1995, 36, 4567, Rotella, D , J Am Chem Soc 1996, 118, 12246 and references cited therein )
- the monomers utilized in the present invention are preferably easily synthesized, in high yields with high diastereo- and enantioselectivity Examples of certain preferred monomers having a syn relationship between the allyhc alcohol and the functional (R) group are depicted in Figure 3 In addition to providing monomers having a svn relationship, the present invention provides monomers having an anti relationship as depicted in Examples 13-29 Thus, the ability to provide monomers having all possible stereoisomers enables the synthesis of compounds and libraries of compounds having significant stei eodiversity
- each monomer contains first (L n and L 21 ) and second (L 12 and L 22 ) terminal functionalities capable of either (1) linking to another monomer in an inter- or intramolecular fashion; (2) being immobilized on the solid support, or (3) attaching to other amino acids or peptides.
- Each monomer also contains an optional linking group binding site (X, or X 2 ) that can be employed to link the monomers together in an intramolecular fashion.
- any or all of the base monomer structures, the terminal functionalities, and the linking group binding sites may contain reactive sites available for further diversification, as is discussed in more detail below.
- first and second terminal functionalities may be employed in accordance with the present invention.
- Terminal functionalities include but are not limited to amines, carboxylic acids, halogenated aromatics for transition metal catalyzed cross coupling reactions, terminal aldehydes for pinacol couplings, terminal alkynes for hydrozirconation, and terminal alkenes for olefin metathesis and nucleophilic addition.
- Figures 4, 5, 6, 7, 8 and 9 show the preferred cross-coupling, pinacol coupling, tandem aldol/Curtius i ⁇ arrangement, hydrozirconization, nucleophilic addition, and N ⁇ K (Nozaki-Hiyama-Kishi (Furstrser et al., J. Am. Chem. Soc. 1996, 118, 12349)) coupling, respectively.
- the second terminal functionality (L 12 j of the first monomer and the first terminal functionality (L 21 ) of the second monomer are each alkenes, selected to be capable of reacting with one another.
- first terminal functionality (L ⁇ ) of the first monomer and the second terminal functionality (L 22 ) of the second monomer is either an amine or carboxylic acid capable of further reacting with amino acids.
- at least one of the first terminal functionality (L n ) of the first monomer and the second terminal functionality (L 22 ) of the second monomer is selected for linkage to a solid phase resin.
- linking group binding sites may be employed in accordance with the present invention, so long as the binding site can be reacted with a linking reagent to add a linking group to the monomer.
- the linking group then reacts to link the first and second monomers to one another.
- linking reagents include sulfonyl chloride, dimethyl dichlorosilane, diisopropylamino chlorophosphoramidite and metals (such as boron and titanium) that are capable of temporary binding as a linker.
- metals such as boron and titanium
- linking reagents can be employed to generate mixed carbonates (R and R'), carbamates, disulfides. ureas, acetals, ortho esters, phosphates and oxides as linking groups.
- Linking group binding sites can include any functionality capable of reaction with the selected linking reagent.
- the linking group binding site comprises a carbon, oxygen, nitrogen, or sulfur atom, for example a hydroxyl, amino, or thiol group, through which the linking group becomes attached to the monomer.
- L u and L 1 preferably each comprise the same or different terminal reactive moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic, aldehyde and vinyl halide;
- R,, R 2 and R 3 are preferably selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene cyclohexyl, benzyl, heteroaryl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl;
- X preferably comprises a functional moiety selected from the group consisting of carboxyl, amino, gem-dialkyl, and methylene;
- X preferably comprises a functionality containing nitrogen, oxygen, sulfur or carbon;
- L preferably comprises a group, including but not limited to mixed carbonates
- Scheme 3 depicts the first monomer of Scheme 2 after linkage to a second monomer.
- the two monomers connected by the linking group are in a syn relationship to each other.
- L ⁇ , L 12 , L 21 , and L 22 each comprise the same or different terminal reactive moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic, aldehyde and vinyl halide;
- R 1; R 2 and R 3 are preferably selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene cyclohexyl, benzyl, heteroaryl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl;
- X 3 and X. ⁇ each preferably comprises a functional moiety selected from the group consisting of carboxyl, amino, gem-dialky
- the first and second monomers are structurally related to one another so that the second monomer can be produced by chemical conversion of the first.
- Figures 1 1, 12 and 13 depict preferred embodiments of the present invention in which first and second monomers (depicted as C-terminal and N-terminal monomers, respectively) are synthesized convergently using known Evans' aldol chemistry (Evans et al.. J. Am. Chem. Soc. 1982, 104. 1737).
- R can be, but is not limited to, methyl, ethyl, n-propyl, iso-propyl, cyclopentyl, phenoxy, methoxy, bromide, and methylene cyclohexyl, benzyl, chloride, carboxyalkyl, carboxyaryl, arylalkyl, thio, hydroxyl, and heteroaryl functionalities.
- R can be, but is not limited to, methyl, ethyl, n-propyl, iso-propyl, cyclopentyl, phenoxy, methoxy, bromide, and methylene cyclohexyl, benzyl, chloride, carboxyalkyl, carboxyaryl, arylalkyl, thio, hydroxyl, and heteroaryl functionalities.
- Another important aspect of the monomers utilized in the present invention includes the ability to produce both syn and anti products. Specifically, Examples 1-12 present the synthesis of syn products, and examples 13-19 present the synthesis of anti products.
- Still another important aspect of the particular monomers produced according to Figures 1 1 and 12 is their ability to be converted into useful second monomers by utilizing the Curtius rearrangement as shown below in Figures 12 and 13.
- the Curtius rearrangement yields a stereochemically pure second monomer from the first monomer and thus under these reaction conditions, the stereocenters are rigidly set.
- stereochemically pure monomers can be obtained from other rearrangements such as the Hofmann, Lossen and Schmidt Rearrangements, as shown generally in Figure 14.
- the capability of controlling the stereochemistry of the present invention allows the development of peptidomimetics or libraries of peptidomimetics that may have certain desired conformational and binding properties.
- a first monomer may be reacted with a second monomer, or a sole monomer may be diversified.
- the reaction of the first and second monomers may occur inter-or intramolecularly. That is, if the monomers have already been linked to one another as described above (see for example, Scheme 3), their subsequent reaction is intramolecular; if they have not been so linked, their reaction is intermolecular. Whether the reaction employed is intermolecular or intramolecular, the monomers are selected to have terminal functional moieties L )2 and L 21 capable of reaction with one another so that the monomers become attached.
- L I2 and L 21 are both terminal alkenes.
- each of L 12 and L 21 may be selected from the group comprising but not limited to alkenes, alkynes, amines, carboxylic acids, halogenated aromatics, aldehydes, and vinyl halides.
- the first and second monomers each have a linking group binding site and are linked together by means of a crosslinking reagent as shown in Figure 15.
- the first and second monomers each have a heteroatom-containing linking group binding site and are linked together by means of a silicon crosslinker such as dimethyldichlorosilane as shown in Figure 16.
- the monomers each contain a hydroxyl or amine linking group binding site and diisopropylamino chlorophosphoramidite is utilized as a linking reagent as shown in Figure 17.
- these linked monomers comprise alkene terminal reactive moieties and thus are subjected to reaction conditions to effect an intramolecular metathesis reaction to generate an alkene moiety.
- the resultant linker provides a phosphorous moiety that can act as an additional site for functionalization. For example, oxidation can be employed to generate an oxide, which will enable further diversification.
- the generation of a phosphate is advantageous because phosphorylation of peptides is a key step in many intracellular processes, and therefore peptidomimetic structures containing a phosphate-like moiety might be expected to interact with signaling proteins.
- Other preferred linking reagents include, but are not limited to sulfonyl chloride and suitable reagents containing metals such as boron or titanium (e.g., TiCl 4 )
- Olefin metathesis is effected by using transition metal catalysts for ring closing metathesis reactions.
- transition metal catalysts for ring closing metathesis reactions.
- Grubbs' catalyst has been utilized for these types of reactions, however, recently, more efficient versions of this catalyst have been developed (see. Tet. Lett., 1999, 40, 2247) to effect ring closing metathesis reactions for more difficult substrates.
- the mixture of compounds obtained from the non-hydrogenated product can be separated by subsequent deprotection and cyclization, for example as shown in Figure 19.
- Preferred intermolecular embodiments of the present invention also include linking the first and second monomers in a transition metal mediated crosscoupling reaction, such as the palladium catalyzed Heck Reaction as shown in Scheme 4, in which a haloaromatic first monomer is reacted with a second monomer under palladium (0) catalysis to yield an aromatic backbone and olefin that can be further functionalized.
- a transition metal mediated crosscoupling reaction such as the palladium catalyzed Heck Reaction as shown in Scheme 4, in which a haloaromatic first monomer is reacted with a second monomer under palladium (0) catalysis to yield an aromatic backbone and olefin that can be further functionalized.
- the amine functionality can also be deprotected and peptide coupling continued.
- Preferred intermolecular embodiments of the present invention also include a pinacol coupling followed by elimination to yield an alkene, bond construction through tandem aldol reaction followed by Curtius rearrangement, hydrozirconization of terminal alkynes, and nucleophilic addition involving terminal alkenes, and NHK coupling, as shown in Figures 5, 6, 1, 8, and 9 respectively.
- the first monomer instead of being reacted with a second monomer as described above, is reacted with a reactive moiety to yield a molecule containing a diversifiable segment unit and diversifiable functional groups (R).
- ⁇ diastereoselective cycloaddition based upon the work of Carreira et al. (J. Am. Chem. Soc. 1997, 119, 8379), is shown in Figure 20, in which dipolarophiles are reacted with Me 3 SiCHN 2 to yield ⁇ 2 -pyazolines.
- Each of the structures shown in Figure 20 contain reactive moieties which may be further functionalized. Alternatively, these reactive moieties are capable of attachment of biomolecules. preferably peptides, to yield complex compounds and libraries of compounds.
- work from the thesis of Ann Weber is shown in Figure 21 in which a diversifiable monomer is generated which contains four points of diversity. This moiety is also capable of attachment of biomolecules, such as peptides, to yield complex compounds and libraries of compounds.
- each of the monomers utilized in the invention is capable of functionalization at one or more sites. That is, each monomer may contain functionalizable moieties as part of the base monomer structure, the terminal functionalities, and the linking group binding site. Where the monomers are linked together prior to attachment through an intramolecular reaction, the linking reagents and therefore the linker attaching the monomers, may also contain one or more functionalizable sites.
- These functionalizable sites may be diversified with any desirable moiety, including but not limited to hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene cyclohexyl, benzyl, heteroaryl, aryloxy, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio, and hydroxyl.
- This functionalization is in general limited to those functionalities that will not participate in undesirable side reactions during the coupling reaction. For example, olefins, more particularly terminal olefins, interfere with the coupling process because of their ability to participate in undesirable side reactions.
- monomers and/or linking reagents can be functionalized either before or after being reacted, and thus the chemistry employed must be compatible with existing functionalities.
- the monomers are first reacted to produce a single core molecule that is subsequently functionalized and diversified.
- the diversification reactions are preferably performed according to combinatorial approaches such as split-and-pool or parallel synthesis.
- the reactions are performed to produce libraries having at least approximately 10 members, more preferably at least approximately 1,000 members, and most preferably 10,000 to about 1,000,000 or about 10,000,000 members.
- Scheme 4 represents one particular embodiment of a core molecule available for functionalization according to the present invention.
- L n and L 22 each comprise the same or different terminal reactive moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne. amine, carboxylic acid, halogenated aromatic, aldehyde and vinyl halide;
- R b R 2 and R 3 are preferably selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene cyclohexyl, benzyl, heteroaryl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl;
- X 3 and X 4 each preferably comprises a functional moiety selected from the group consisting of carboxyl, amino, gem-dialkyl, and methylene;
- X, and X 2 preferably each comprise a functionality containing nitrogen, oxygen, sulfur or carbon;
- L preferably comprises a group, including but not limited to mixed carbonates (R and R'
- the structure depicted in Scheme 4 is available for randomization and diversification at several sites, allowing for the rapid synthesis of a library of compounds capable of emulating peptidic functions and structures, although these compounds are not necessarily required to emulate peptidic structure.
- diversification can be achieved through functionalization at the R groups, represented by R,, R 2 and R 3 as shown in Scheme 4.
- R groups represented by R,, R 2 and R 3 as shown in Scheme 4.
- various functionalities can be substituted including but not limited to hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene cyclohexyl, benzyl, heteroaryl, aryloxy. carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio, and hydroxyl.
- L u and L 22 each comprise the same or different terminal reactive moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic, aldehyde and vinyl halide;
- R b R 2 and R 3 are preferably selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene cyclohexyl, benzyl, heteroaryl, aryloxy, heteroaryl, carboxyl, carboxalkyl.
- n variants of reactant A such as a carboxylic acid
- m variants of reactant B such as an amide
- a solid phase synthesis technique is utilized, in which the desired scaffold structures are attached to the solid phase directly or though a linking unit, as discussed above.
- Advantages of solid phase techniques include the ability to more easily conduct multi-step reactions and the ability to drive reactions to completion because excess reagents can be utilized and the un reacted reagent washed away.
- One of the most significant advantages of solid phase synthesis is the ability to use a technique called "split and pool", in addition to the parallel synthesis technique, developed by Furka. (Furka et al., Abstr. 14th Int. Congr. Biochem., Prague, Czechoslovakia, 1988, 5. 47, Furka et al.. Int. J. Pept.
- Examples of particular preferred alternative encoding techniques that can be utilized in the present invention include, but are not limited to, spatial encoding techniques, graphical encoding techniques, including the "tea bag” method, chemical encoding methods, and spectrophotomet ⁇ c encoding methods
- Spatial encoding refers to recording a reaction ' s history based on its location
- Graphical encoding techniques involve the coding of each svnthesis platform to permit the generation of a relational database
- Examples of preferred spectrophotomet ⁇ c encoding methods include the use of mass spectroscopy, fluorescence emission, and nuclear magnetic resonance spectroscopy
- chemical encoding methods are utilized, which uses the structure of the reaction product to code for its identity Decoding using this method can be performed on the solid phase or off of the solid phase
- the techniques described herein allow preparation of a library of peptide derivatives corresponding to a known active sequence except that two or three residues of the sequence are replaced with an inventive library
- This peptide derivative library can readilv be screened to identify those compounds within it that retain the peptide activity of interest In this way, a portion of the peptide is "morphed" into another compound that retains the peptide activity
- the method, compounds, and libraries of the present invention can be utilized in various disciplines Any available method may be employed to screen the libraries produced according to the present invention to identify those with desirable characteristics for a selected application.
- the present invention can be utilized to produce peptidomimetic compounds that control (i.e., promote or inhibit) cell functions.
- Such compounds may be formulated and utilized as therapeutic pharmaceuticals.
- therapeutic pharmaceuticals through interactions with cellular receptors, can control HIV production, cell proliferation, viral replication, gene expression, or any other cell signaling process.
- a morphed segment produced according to the present invention can be embedded in a SH 2 binding peptide, as shown in Figure 25.
- Inventive peptidomimetic or stereodiverse compounds are also useful in the area of materials science. Because of the reactive moieties present at the terminal ends of these compounds, molecules such as lipids and other polymeric molecules may be attached and thus generate potentially important biomaterials. It will be appreciated by one of ordinary skill in the art that the present invention is not intended to be limited to the abovementioned uses, but rather may be employed in many contexts and disciplines.
- Example 11 In a 50 ml Corning plastic test tube, compound 11 (166 mg, 0 25 mmoles) was dissolved in 1 ml of THF and cooled down to 0°C A solution of HF in pyridine (71 ml, 2.5 mmoles, Aldrich 18,422-5) was added dropwise, the reaction was allowed to warm up to room temperature and stirred for additional 30 minutes at room temperature After that time, the reaction was carefully quenched with 10 ml of 1 0M Na 2 CO 3 (vigorous foaming), extracted (3X) with EtOAc, dried with anhydrous MgSO , filtered and concentrated under vacuum The crude product was purified by flash chromatography (3 1 hexanes/EtOAc+1 0% MeOH) Yield 85 mg (50%) Note The low yield is most likely caused by the residual catalyst decomposition products increasing the weight of compound 11 before the deprotection
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
The present invention provides a system for the production of chemical compounds and libraries of compounds that are complex, stereochemically and regioselectively pure, and may mimic the structural or functional properties of a peptide. The invention provides methods for producing collections of peptidomimetic compounds which, in one preferred embodiment, comprises (1) providing two diversifiable monomers containing terminal reactive moieties; (2) reacting the monomers under conditions that allow for the control of stereochemistry as well as chemoselectivity; and (3) generating diversifiable isolable compounds or libraries of compounds. In another preferred embodiment, a collection of peptidomimetic compounds is provided by (1) providing at least one diversifiable monomer containing terminal reactive moieties; (2) reacting the monomer with a reagent under conditions that allow for the control of stereochemistry as well as chemoselectivity; and (3) generating diversifiable isolable compounds or libraries of compounds. In another broader aspect, the present invention provides for the synthesis of a collection of compounds comprising peptidomimetics and non-peptidomimetics alike having stereodiversity. This method involves the steps of (1) selecting desired synthetic precursors having a predefined stereochemical relationship; (2) reacting the synthetic precursors so that a compound having a specific stereochemistry is obtained; and (3) repeating these steps of selecting and reacting until a desired library of compounds having stereochemical diversity is obtained. In certain preferred embodiments, a library of compounds having only diversity of stererochemistry is provided. In certain other preferred embodiments, a library of compounds having structural diversity and stereochemical diversity is provided. The present invention also provides various chemical compounds useful in the inventive methods for production of complex peptidomimetic libraries. The peptidomimetic and stereodiverse compounds of the inventive method are useful for interactions with receptors in cells and may emulate the structure and functionality of peptides.
Description
SYNTHESIS OF COMPOUNDS AND LIBRARIES OF COMPOUNDS
Priority Information
This application claims priority to the provisional application, 60/079,035, entitled "Synthesis of Compounds with Peptide Characteristics", filed March 23, 1998, the entire contents of which are incorporated herein by reference.
Background of the Invention
The important biological roles that peptides play as hormones, enzyme inhibitors, substrates, neurotransmitters, and neuromediators has led to the widespread use of peptides in medicinal chemistry as therapeutic agents. Through binding to receptors or enzymes, peptides are able to influence cell-cell communication and control vital cell functions such as metabolism, immune defense and reproduction. (Babine et al., Chem. Rev. 1997, 9~, 1359) Unfortunately, the utility of peptides as drugs is severely limited by several factors, including their rapid degradation by peptidases under physiological conditions, their poor cell permeability, and their lack of binding specificity resulting from conformational flexibility.
In response to these unfavorable characteristics of peptide drugs, many research groups have developed strategies for the design and synthesis of chemical compounds, known as "peptidomimetics", in which sensitive peptide moieties are removed and replaced with more robust functionalities. In particular, researchers have sought to improve peptide stability and cell permeability by replacing the amide functionality with groups such as hydroxyethylene, (E)-alkenes, carba groups and phosphonamide groups (Gante, J., Angeλv. Chem. Int. Ed. Engl 1994, 33, 1699-1720, and references cited therein). In most cases, these peptidomimetic compounds have been prepared one at a time.
A few researchers have also attempted to design combinatorial strategies to produce peptidomimetic libraries (Boger, D, WO 96/03424; Ellman, J., U.S. Patent No. 5,545,568. Simon, R. et al., Proc. Natl Acad. Sci. USA 1992, 89, 9367; Bartlett et al., Proc. Natl Acad. Sci. USA 1992, 89, 9367). Unfortunately, these efforts are often limited by lack of
stereochemical complexity and control, and/or by restricted ability to substitute base molecules Also, existing peptidomimetic strategies generally rely on a fixed structure to mimic the peptide bond, and do not allow subsequent modification and diversification of this structure There remains a need to develop a synthetic strategy capable of producing complex, highly diversified libraries of compounds that can act as peptidomimetics There is a particular need for methods and compounds that allow significant stereochemical control and functional group diversity in the production of such libraries Furthermore, because of the importance of stereochemical complexity in the synthesis of these and other libraries, there also remains a need for the development of stereodiverse compounds and libraries of compounds
Summary of the Invention
The present invention provides a system for the production of chemical compounds that are capable of mimicking structural and/or functional properties of peptides The inventive system allows simultaneous production of multiple complex compounds, and provides for significant stereochemical and regiochemical control, as well as functional group diversity While the prior art describes attempts to reproduce a particular peptide structure the present invention provides a broad new approach to the production of compounds with certain structural and/or functional properties characteristic of peptides The term "peptidomimetic", therefore, when used herein in the context of the present invention, encompasses more expansive concepts than are found in the prior art In addition to providing a broad new approach to the production of compounds with certain structural and/or functional characteristics of peptides, the present invention teaches a broad new approach for the synthesis of libraries of compounds having stereochemistry as a diversity element
According to the present invention, both the structure replacing the peptide bond and that replacing the peptide functional group can be modified and diversified Furthermore, the present invention enables not only the diversification of chemical
structure and the synthesis of compounds having peptide characteristics, but also enables the svnthesis of stereodiverse compounds The present invention therefore can be seen as providing methods and compounds that transform peptide functionalities into alternative chemical structures and stereoisomers of these chemical structures In one sense, the invention constitutes a system for "morphing" peptides into other compounds
In one aspect, the present invention provides methods for producing collections of peptidomimetic compounds In certain preferred embodiments, these methods involve (1) providing two diversifiable monomers containing terminal reactive moieties, (2) reacting the monomers under conditions that allow for the control of stereochemistry as well as chemoselectivity, and (3) generating diversifiable, isolable compounds or libraries of compounds In other preferred embodiments, the methods involve (1) providing one diversifiable monomer containing terminal reactive moieties, (2) reacting the monomer with a reagent under conditions that allow for the control of stereochemistry as well as selectivity, and (3) generating diversifiable isolable compounds or hbraπes of compounds As discussed, the present invention provides a system foi the stereochemical control of the svnthesis of compounds and libraries of compounds As will be appreciated by one of ordinary skill in the art, this aspect is not limited to the synthesis of libraries of peptide mimics Rather, the present invention encompasses the broader concept of providing any collection of chemical compounds having stereodiversity Thus, in another aspect, the present invention provides methods for the generation of compounds and libraries of compounds, peptidomimetics and non-peptidomimetics alike, having stereochemical diversity This method involves the steps of (1) selecting desired synthetic precursors having a predefined stereochemical relationship, (2) reacting the synthetic precursors so that a compound having a specific stereochemistry is obtained, and (3) repeating these steps of selecting and reacting until a desired library of compounds having stereochemical diversity is obtained In preferred embodiments, a library of compounds having only diversity of stereochemistry is provided For these embodiments, it is particularly preferred that at least 4 stereoisomers are provided, more particularly preferred that at least 8 stereoisomers are provided, and most particularly preferred that at least 16 stereoisomers are provided In other preferred embodiments, a library of compounds having structural
diversity and stereochemical diversity is provided Thus, for each compound having a specific structural formula, it is particularly preferred that for each structure at least 4 stereoisomers are provided, more particularly preferred that at least 8 stereoisomers are provided, and most particularly preferred that at least 16 stereoisomers are provided The present invention also provides methods of preparing and screening libraries of compounds generated to mimic desired functional and/or structural aspects of a particular peptide or portion thereof As such, the invention provides methods for "morphing" peptides into alternate chemical compounds
In yet another aspect, the invention provides various chemical compounds useful for production of complex peptidomimetic libraries These compounds may be diversified at the level of functional group units, monomer units, segment units, and biomolecule units Furthermore, each of these units may be diversified structurally, I e , by functional group diversification, or may be diversified stereochemically
Description of the Drawing
Figure 1 depicts the Peptide Morphing strategy of the present invention
Figure 2 depicts a retrosynthetic analysis of a preferred structure of the present invention
Figure 3 depicts certain preferred monomers having a syn relationship between the allyhc alcohol and the functional group
Figure 4 depicts bond construction through palladium coupling
Figure 5 depicts bond construction through pinacol coupling
Figure 6 depicts bond construction through tandem aldol reaction followed by Curtius rearrangement Figure 7 depicts hydrozirconation reactions
Figure 8 depicts a nucleophihc addition reaction
Figure 9 depicts Nozaki-Hiyama-Kishi coupling reactions
Figure 10 depicts attachment of a morphed segment to the resin
Figure 11 depicts synthesis of the C-terminal (first) monomer
Figure 12 depicts the synthesis of the N-rerminal (second) monomer
Figure 13 depicts a convergent and efficient synthesis of monomers Figure 14 depicts Hoffman, Lossen and Schmidt Rearrangements
Figure 15 depicts intramolecular olefin metathesis
Figure 16 depicts reaction of a dimethyldichlorosilane linker with preferred monomers of the invention
Figure 17 depicts reaction of a dusopropyl amino chlorophosphoramidite linker with preferred monomers of the invention
Figure 18 depicts intermolecular olefin cioss metathesis reactions
Figure 19 depicts separation of two libraries generated from intermolecular olefin cross metathesis
Figuie 20 depicts bond construction through cycJoaddition Figure 21 depicts a diversifiable core structure from the thesis of Ann Weber
Figure 22 depicts a directed photolysis reaction using a silicon linker
Figure 23 depicts modification of the olefin functionality
Figure 24 depicts selective protection of a linking moiety on the resin
Figure 25 depicts embedding morphed segment in an SH2 binding peptide Figure 26 depicts a model structure of the binding of a morphed peptide to a SH2 domain
Figure 27 depicts a library of inhibitors of D A glycosylases
Figure 28 depicts a library of synthetic transcriptional regulators
Figure 29 depicts a use for the compounds and libraries of the present invention in the E6 E6-AP system
Figure 30 depicts a use for the compounds and libraries of the present invention in
the remn-angiotensin system
Figure 31 depicts a use for the compounds and the libraries of the present invention as inhibitors of the proteasome.
Figure 32 depicts the synthesis of compound 2 Figure 33 depicts the synthesis of compound 3
Figure 34 depicts the synthesis of compound 4
Figure 35 depicts the synthesis of compound 5
Figure 36 depicts the synthesis of compound 6
Figure 37 depicts the synthesis of compound 7 Figure 38 depicts the synthesis of compound 8
Figure 39 depicts the synthesis of compound 9
Figure 40 depicts the synthesis of compound 10
Figure 41 depicts the synthesis of compound 1 1
Figure 42 depicts the synthesis of compound 12 Figure 43 depicts the synthesis of compound 13
Figure 44 depicts the synthesis of compound 14
Figure 45 depicts the synthesis of compound 15
Figure 46 depicts the synthesis of compound 16
Figure 47 depicts the synthesis of compound 17 Figure 48 depicts the synthesis of compound 18
Figure 49 depicts the synthesis of compound 19
Definitions
"Peptidomimetic". The term "peptidomimetic", as used herein, refers to a chemical compound that, at least in part, mimics one or more structural or functional properties of a peptide As discussed above, the prior art definition of peptidomimetic focuses on
compounds in which one or more of the characteristic chemical moieties of a peptide is substituted with alternative functional groups. The present invention provides a broader concept of peptidomimetic, describing a system for producing a wide variety of chemical compounds that may have one or more structural or functional aspects of biologically active peptides. That is, for the purposes of the present invention., a peptidomimetic does not necessarily refer to a compound that per se imitates the properties of a peptide, but can also refer to a compound in which a segment unit replacement of the amide functionality, which bears no structural relationship to a peptide functionality, is capable of interacting with a biological receptor or ligand with desired specificity. To give but a few specific examples, peptidomimetics include, but are not limited to, compounds in which the amide bond of a peptide is replaced with alkene, hydroxyethylene or carba functionalities. Peptidomimetics also include compounds in which the α-CH group is replaced with aza, C-alkyl, or bora functionalities, among others.
"Combinatorial Library": The term "combinatorial library", as used herein, refers to a collection of compounds produced in a manner that allows "segment units", 'functionality units", "monomer units", "biomolecule units"., or any combination thereof, to be varied in a systematic fashion. The segment unit may be generated from any compatible reaction between monomers (or upon a monomer) that results in a replacement of the amide functionality with any other functionality. The functionality units may be varied on individual monomers, or after monomers have been joined together. These functionality units may be present within the segment unit of the joined monomers, or may be present at other sites within the monomers.
"Biomolecules": The term "biomolecules", as used herein, refers to molecules (e.g., proteins, amino acids, nucleic acids, nucleotides, carbohydrates, sugars, lipids, etc.) that are found in living cells in nature.
"Monomer unit": The term "monomer unit", as used herein, refers in one aspect to a molecule that can be joined together to form another molecule or set of molecules, such as a set of oligomers or polymers. In another aspect "monomer unit", as used herein, refers to a molecule that can be diversified at particular sites on the monomer unit. More particularly, the present invention refers to a monomer that is characterized in that it
contains reactive moieties available for diversification and optionally is characterized by the presence of a reactive moiety that allows linkage of multiple individual monomers by way of a segment unit functionality
"Diversity element" The term "diversity element", as used herein, refers to structural (1 e , functional group diversity), stereochemical, diastereochemical, and/or regiochemical diversity in a particular compound As will be appreciated by one of ordinary skill in the art, the present invention provides for the synthesis of compounds and libraries of compounds having any of these diversity elements alone or in combination with one or more of the other diversity elements "Stereoisomer" The term "stereoisomer", as used herein, refers to a structure of the same constitution as another structure, differing only in the spatial arrangement Stereoisomers are described by specifying their topology and the nature of their relationship to other stereoisomers of the same constitution
"Enantiomer" The term "enantiomer", as used herein, refers to a stereoisomer that is related to another stereoisomer as an object and its mirror image
"Diastereomer" The term "diastereomer", as used herein, refers to a stereoisomer that is related to another stereoisomer in a manner other than as an object and its mirror image For example, one stereogenic center relative to another stereogenic center is different for diastereomers Diastereomers differ from one another both in phvsical properties and in chemical reactivities For example, different diasteriomers generally have different melting points, boiling points, and solubility characteristics
"Stereoselective Reaction" The term "stereoselective reaction" refers to a chemical reaction in which one of the stereoisomeπc products is formed in excess
"Enantioselective Reaction" The term "enantioselective reaction" refers to a chemical reaction in which one of the enantiomeπc products is formed in excess
"Diastereoselective Reaction" The term "diastereoselective reaction" refers to a reaction in which only one of the diastereomeπc products is formed in excess, or one m which the major product is diastereomeπcally pure
"Regioselective Reaction" The term 'regioselective reaction" refers to a reaction in
which an unsymmetrical alkene gives a predominance of one of the two possible addition products. The reaction is regiospecific if one of the products is formed exclusively.
Detailed Description of Certain Preferred Embodiments As discussed above, the present invention provides methods and compounds related to production of complex libraries of chemical compounds with certain structural and/or functional characteristics of peptides. In addition to providing compounds and libraries of peptide-like compounds and methods for their syntheses, the present invention, in a broader aspect, provides for the generation of chemical libraries of peptidomimetics and non- peptidomimetics alike, having stereoisomerism as a diversity element.
In one particularly preferred embodiment, as shown in Figure 1 , the inventive reactions involve steps of (1) providing at least two monomer compounds, each of which has at least two terminal reactive moieties; and (2) reacting the monomers with one another, under conditions that allow for the control of stereochemistry as well as chemoselectivity, so that they become linked together at one of their reactive moieties and generate a segment unit, and (3) generating diversifiable isolable compounds or libraries of compounds. Typically, each monomer contains multiple reactive moieties, and additional reactions are performed to functionalize these moieties either before or after the monomers are linked to one another, so that highly complex libraries are produced. In another particularly preferred embodiment, the inventive reactions involve steps of (1) providing at least one monomer compound, which has at least two terminal reactive moieties; (2) reacting the monomer with a reagent that allows for the control of stereochemistry as well as chemoselectivity, and (3) generating diversifiable isolable compounds or libraries of compounds with characteristics reminiscent of peptides. One advantage of the inventive synthetic system is that it allows simultaneous production of a large number of complex peptidomimetic compounds under conditions of controlled stereo- and regio-selectivity. Preferred peptidomimetic compounds produced according to the present invention contain both peptide bond and functional group substitutions when compared with peptides. Thus, the present invention represents a
broadening of the conception of peptidomimetics In fact, another advantage of the present system is that these substitutions are not necessarily limited to compounds that represent structural mimics of peptides, as might be found in the prior art Instead, the inventive system, through a segment unit replacement, enables the maximization of the diversification of structures The invention therefore enables the discovery of heretofore unanticipated interactions of compounds, that bear little or no structural relation with peptides, with biological receptors or hgands
As will be appreciated by one of ordinary skill in the art, the method of the present invention and the ability to control the specific stereochemistry has a broader context than the immediate application to peptidomimetics Rather, the present invention also provides for the generation of libraries having stereodiversity Thus, in another aspect the present invention provides methods for the generation of compounds and libraries of compounds, peptidomimetics and non-peptidomimetics alike, having stereochemical diversity This method involves the steps of (1) selecting desired synthetic precursors having a predefined stereochemical relationship, (2) reacting the synthetic precursors so that a compound having a specific stereochemistry is obtained, and (3) repeating these steps of selecting and reacting until a desired library of compounds having stereochemical diversity is obtained In preferred embodiments, a library of compounds having only diversity of stereochemistry is provided For these embodiments, it is particularly preferred that at least 4 stereoisomers are provided, more particularly preferred that at least 8 stereoisomers are provided, and most particularly preferred that at least 16 stereoisomers are provided In other preferred embodiments, a library of compounds having structural diversity and stereochemical diversity is provided Thus, for each compound having a specific structural formula, it is particularly preferred that for each structure at least 4 stereoisomers are provided, more particularly preferred that at least 8 stereoisomers are provided, and most particularly preferred that at least 16 stereoisomers are provided
Various characteristics of the monomers and reactions utilized in preferred embodiments of the present invention are discussed in more detail below, certain examples of inventive reactions and compounds are also presented
Monomers
As mentioned above, preferred embodiments of the invention utilize either a single monomer or at least two monomers. Figure 2 depicts the retrosynthetic analysis of a preferred diversifiable peptidomimetic core, in which two monomers are used to generate the desired structure. Each monomer is characterized either by the presence of a reactive moiety that facilitates the linkage of the monomers to one another by way of a segment unit, or by the presence of a reactive moiety that facilitates the reaction of the monomers with chemical reagents. Each monomer preferably also contains additional reactive moieties available for diversification, so that the peptidomimetic compounds produced according to the present invention can be diversified both at the level of the segment unit structure and at the level of functional groups. Preferably, each monomer contains at least one terminal reactive moiety that allows the monomer to be linked to a biomolecule. In particularly preferred embodiments, each monomer contains a moiety available for linkage to a peptide, so that the inventive peptidomimetic compounds can readily be embedded within a peptide chain.
The monomers utilized in accordance with the present invention are selected to allow for significant control of the stereo- and regio-chemistry of the reactions that they undergo. Furthermore, as will be appreciated by those of ordinary skill in the art, and is discussed in more detail below, in embodiments utilizing at least two monomers, each monomer is selected to react with the other monomer being employed. Thus, the chemical nature of the moiety on the first monomer that is available for linkage to the second monomer places constraints on the nature of the acceptable second monomer moiety and therefore limits the selection of the second monomer, and also limits the resulting stereoselectivity. In certain preferred embodiments of the invention, at least one monomer contains a reactive moiety available for linkage to the solid phase. Such linkage may be direct or indirect. For example, the monomer may be linked to another molecule, preferably a biomolecule (and most preferably a peptide) that is itself linked to the solid phase. Methods of linking compounds to the solid phase are known in the art and a variety of methods may be employed in the present invention. (See, for example, Brown, "Recent
Developments in Solid-Phase Organic Synthesis" Contemporary Organic Synthesis, 1997, p 216, Hiroshige et al , Eet lett 1995, 36, 4567, Rotella, D , J Am Chem Soc 1996, 118, 12246 and references cited therein )
The monomers utilized in the present invention are preferably easily synthesized, in high yields with high diastereo- and enantioselectivity Examples of certain preferred monomers having a syn relationship between the allyhc alcohol and the functional (R) group are depicted in Figure 3 In addition to providing monomers having a svn relationship, the present invention provides monomers having an anti relationship as depicted in Examples 13-29 Thus, the ability to provide monomers having all possible stereoisomers enables the synthesis of compounds and libraries of compounds having significant stei eodiversity
Scheme 1 below, depicts a general scheme of a particularly preferred embodiment of the present invention for the synthesis of inventive compounds and libraries of compounds
Lin in- group omdin-: Mte
Monomer 1 Monomer 2
Scheme 1
As depicted, each monomer contains first (Ln and L21) and second (L12 and L22) terminal functionalities capable of either (1) linking to another monomer in an inter- or intramolecular fashion; (2) being immobilized on the solid support, or (3) attaching to other amino acids or peptides. Each monomer also contains an optional linking group binding site (X, or X2) that can be employed to link the monomers together in an intramolecular fashion. Furthermore, any or all of the base monomer structures, the terminal functionalities, and the linking group binding sites may contain reactive sites available for further diversification, as is discussed in more detail below.
As will be appreciated by those of ordinary skill in the art, a wide variety of first and second terminal functionalities may be employed in accordance with the present invention. As will also be appreciated, the selection of these functionalities for each monomer will depend on the nature of the moiety with which each functionality is to react. Terminal functionalities that may be employed include but are not limited to amines, carboxylic acids, halogenated aromatics for transition metal catalyzed cross coupling reactions, terminal aldehydes for pinacol couplings, terminal alkynes for hydrozirconation, and terminal alkenes for olefin metathesis and nucleophilic addition. Figures 4, 5, 6, 7, 8 and 9 show the preferred cross-coupling, pinacol coupling, tandem aldol/Curtius i ^arrangement, hydrozirconization, nucleophilic addition, and NΗK (Nozaki-Hiyama-Kishi (Furstrser et al., J. Am. Chem. Soc. 1996, 118, 12349)) coupling, respectively. In one particularly preferred embodiment, the second terminal functionality (L12j of the first monomer and the first terminal functionality (L21) of the second monomer are each alkenes, selected to be capable of reacting with one another. In another particularly preferred embodiment, one or both of the first terminal functionality (Lπ) of the first monomer and the second terminal functionality (L22) of the second monomer is either an amine or carboxylic acid capable of further reacting with amino acids. In yet another preferred embodiment, at least one of the first terminal functionality (Ln) of the first monomer and the second terminal functionality (L22) of the second monomer is selected for linkage to a solid phase resin. Scheme 10 depicts the attachment of the diversifiable peptidomimetic structure of the present invention to the resin. Those of ordinary skill in the art will appreciate that any of a variety of linking
group binding sites may be employed in accordance with the present invention, so long as the binding site can be reacted with a linking reagent to add a linking group to the monomer. The linking group then reacts to link the first and second monomers to one another.
Representative linking reagents include sulfonyl chloride, dimethyl dichlorosilane, diisopropylamino chlorophosphoramidite and metals (such as boron and titanium) that are capable of temporary binding as a linker. One of ordinary skill in the art will realize that other linking reagents can be employed to generate mixed carbonates (R and R'), carbamates, disulfides. ureas, acetals, ortho esters, phosphates and oxides as linking groups.
Linking group binding sites can include any functionality capable of reaction with the selected linking reagent. Preferably, the linking group binding site comprises a carbon, oxygen, nitrogen, or sulfur atom, for example a hydroxyl, amino, or thiol group, through which the linking group becomes attached to the monomer. Scheme 2. below, depicts one particular preferred embodiment of a monomer for use in the present invention, in which Lu and L1 preferably each comprise the same or different terminal reactive moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic, aldehyde and vinyl halide; R,, R2 and R3 are preferably selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene cyclohexyl, benzyl, heteroaryl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl; X preferably comprises a functional moiety selected from the group consisting of carboxyl, amino, gem-dialkyl, and methylene; X, preferably comprises a functionality containing nitrogen, oxygen, sulfur or carbon; and L preferably comprises a group, including but not limited to mixed carbonates (R and R'), carbamates, disulfides, ureas, acetals, ortho esters, phosphates and oxides, produced by reaction with a linking reagent.
Scheme 2
Scheme 3 depicts the first monomer of Scheme 2 after linkage to a second monomer. In a particularly preferred embodiment, the two monomers connected by the linking group are in a syn relationship to each other. Preferably Lπ , L12, L21, and L22 each comprise the same or different terminal reactive moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic, aldehyde and vinyl halide; R1; R2 and R3 are preferably selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene cyclohexyl, benzyl, heteroaryl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl; X3 and X.ι each preferably comprises a functional moiety selected from the group consisting of carboxyl, amino, gem-dialkyl, and methylene; X, and X2 preferably each comprise a functionality containing nitrogen, oxygen, sulfur or carbon; and L preferably comprises a group, including but not limited to mixed carbonates (R and R'), carbamates, disulfides, ureas, acetals, ortho esters, phosphates and oxides, produced by reaction with a linking reagent. As will be appreciated by one of ordinary skill in the art, these monomers can be attached to a solid support unit, or may also be attached to a biomolecule or a polymer. The further treatment of such linked monomers is discussed more in detail below.
Scheme 3
In one particularly preferred embodiment of the present invention, the first and second monomers are structurally related to one another so that the second monomer can be produced by chemical conversion of the first. For example, Figures 1 1, 12 and 13 depict preferred embodiments of the present invention in which first and second monomers (depicted as C-terminal and N-terminal monomers, respectively) are synthesized convergently using known Evans' aldol chemistry (Evans et al.. J. Am. Chem. Soc. 1982, 104. 1737).
These particular monomers are especially useful because they can be obtained in high yield. Furthermore, the monomer is capable of extensive diversification. For example, R can be, but is not limited to, methyl, ethyl, n-propyl, iso-propyl, cyclopentyl, phenoxy, methoxy, bromide, and methylene cyclohexyl, benzyl, chloride, carboxyalkyl, carboxyaryl, arylalkyl, thio, hydroxyl, and heteroaryl functionalities. One of ordinary skill in the art will realize that the diversification is only limited by the compatibility of the particular functionality with subsequent chemical reactions.
Another important aspect of the monomers utilized in the present invention includes the ability to produce both syn and anti products. Specifically, Examples 1-12 present the synthesis of syn products, and examples 13-19 present the synthesis of anti products.
Yet another important aspect of the particular monomers produced according to Figures 1 1 and 12 is their ability to be converted into useful second monomers by utilizing the Curtius rearrangement as shown below in Figures 12 and 13. The Curtius rearrangement yields a stereochemically pure second monomer from the first monomer and
thus under these reaction conditions, the stereocenters are rigidly set. In addition, stereochemically pure monomers can be obtained from other rearrangements such as the Hofmann, Lossen and Schmidt Rearrangements, as shown generally in Figure 14. The capability of controlling the stereochemistry of the present invention allows the development of peptidomimetics or libraries of peptidomimetics that may have certain desired conformational and binding properties.
Reacting the Monomers
Once appropriate monomers are selected to have the desired structural and reactive characteristics discussed above, a first monomer may be reacted with a second monomer, or a sole monomer may be diversified. In multiple monomer embodiments, the reaction of the first and second monomers may occur inter-or intramolecularly. That is, if the monomers have already been linked to one another as described above (see for example, Scheme 3), their subsequent reaction is intramolecular; if they have not been so linked, their reaction is intermolecular. Whether the reaction employed is intermolecular or intramolecular, the monomers are selected to have terminal functional moieties L)2 and L21 capable of reaction with one another so that the monomers become attached. In particularly preferred embodiments of the invention, LI2 and L21 are both terminal alkenes. Alternatively, each of L12 and L21 may be selected from the group comprising but not limited to alkenes, alkynes, amines, carboxylic acids, halogenated aromatics, aldehydes, and vinyl halides.
In an intramolecular reaction according to the present invention, the first and second monomers (depicted as C-terminal and N-terminal monomers, respectively) each have a linking group binding site and are linked together by means of a crosslinking reagent as shown in Figure 15. In a particularly preferred embodiment of the present invention, the first and second monomers each have a heteroatom-containing linking group binding site and are linked together by means of a silicon crosslinker such as dimethyldichlorosilane as shown in Figure 16. In another particularly preferred embodiment of the invention, the monomers each contain a hydroxyl or amine linking group binding site and diisopropylamino chlorophosphoramidite is utilized as a linking reagent as shown in Figure
17. It is particularly preferred that these linked monomers comprise alkene terminal reactive moieties and thus are subjected to reaction conditions to effect an intramolecular metathesis reaction to generate an alkene moiety. One particular advantage of this approach is that the resultant linker provides a phosphorous moiety that can act as an additional site for functionalization. For example, oxidation can be employed to generate an oxide, which will enable further diversification. Additionally, the generation of a phosphate is advantageous because phosphorylation of peptides is a key step in many intracellular processes, and therefore peptidomimetic structures containing a phosphate-like moiety might be expected to interact with signaling proteins. Other preferred linking reagents include, but are not limited to sulfonyl chloride and suitable reagents containing metals such as boron or titanium (e.g., TiCl4)
One example of a preferred inventive intermolecular reaction is depicted in Figure
18, in which an olefin metathesis reaction yields two potential libraries. Olefin metathesis is effected by using transition metal catalysts for ring closing metathesis reactions. Traditionally, Grubbs' catalyst has been utilized for these types of reactions, however, recently, more efficient versions of this catalyst have been developed (see. Tet. Lett., 1999, 40, 2247) to effect ring closing metathesis reactions for more difficult substrates. The mixture of compounds obtained from the non-hydrogenated product can be separated by subsequent deprotection and cyclization, for example as shown in Figure 19. Preferred intermolecular embodiments of the present invention also include linking the first and second monomers in a transition metal mediated crosscoupling reaction, such as the palladium catalyzed Heck Reaction as shown in Scheme 4, in which a haloaromatic first monomer is reacted with a second monomer under palladium (0) catalysis to yield an aromatic backbone and olefin that can be further functionalized. Furthermore, the amine functionality can also be deprotected and peptide coupling continued.
Preferred intermolecular embodiments of the present invention also include a pinacol coupling followed by elimination to yield an alkene, bond construction through tandem aldol reaction followed by Curtius rearrangement, hydrozirconization of terminal alkynes, and nucleophilic addition involving terminal alkenes, and NHK coupling, as shown in Figures 5, 6, 1, 8, and 9 respectively.
In preferred single-monomer embodiments of the present invention, the first monomer, instead of being reacted with a second monomer as described above, is reacted with a reactive moiety to yield a molecule containing a diversifiable segment unit and diversifiable functional groups (R). For example, ε diastereoselective cycloaddition, based upon the work of Carreira et al. (J. Am. Chem. Soc. 1997, 119, 8379), is shown in Figure 20, in which dipolarophiles are reacted with Me3SiCHN2 to yield Δ2-pyazolines. Each of the structures shown in Figure 20 contain reactive moieties which may be further functionalized. Alternatively, these reactive moieties are capable of attachment of biomolecules. preferably peptides, to yield complex compounds and libraries of compounds. Additionally, work from the thesis of Ann Weber is shown in Figure 21 in which a diversifiable monomer is generated which contains four points of diversity. This moiety is also capable of attachment of biomolecules, such as peptides, to yield complex compounds and libraries of compounds.
Diversification and Combinatorial Synthesis
As discussed above, the present invention provides a system for the production of diverse, complex peptidomimetic and/or stereodiverse libraries. As already noted, each of the monomers utilized in the invention is capable of functionalization at one or more sites. That is, each monomer may contain functionalizable moieties as part of the base monomer structure, the terminal functionalities, and the linking group binding site. Where the monomers are linked together prior to attachment through an intramolecular reaction, the linking reagents and therefore the linker attaching the monomers, may also contain one or more functionalizable sites. These functionalizable sites may be diversified with any desirable moiety, including but not limited to hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene cyclohexyl, benzyl, heteroaryl, aryloxy, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio, and hydroxyl. This functionalization, however, is in general limited to those functionalities that will not participate in undesirable side reactions during the coupling reaction. For example, olefins, more particularly terminal olefins, interfere with the coupling process because of their ability to participate in undesirable side reactions. Those of ordinary skill in the art will appreciate that monomers and/or linking
reagents can be functionalized either before or after being reacted, and thus the chemistry employed must be compatible with existing functionalities. Preferably, the monomers are first reacted to produce a single core molecule that is subsequently functionalized and diversified. The diversification reactions are preferably performed according to combinatorial approaches such as split-and-pool or parallel synthesis. Preferably, the reactions are performed to produce libraries having at least approximately 10 members, more preferably at least approximately 1,000 members, and most preferably 10,000 to about 1,000,000 or about 10,000,000 members.
Scheme 4 represents one particular embodiment of a core molecule available for functionalization according to the present invention.
Scheme 4
Preferably Ln and L22 each comprise the same or different terminal reactive moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne. amine, carboxylic acid, halogenated aromatic, aldehyde and vinyl halide; Rb R2 and R3 are preferably selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene cyclohexyl, benzyl, heteroaryl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl; X3 and X4 each preferably comprises a functional moiety selected from the group consisting of carboxyl, amino, gem-dialkyl, and methylene; X, and X2 preferably each comprise a functionality containing nitrogen, oxygen, sulfur or carbon; L preferably comprises a group, including but not limited to mixed carbonates (R and R'), carbamates, disulfides, ureas, acetals, ortho esters, phosphates and oxides, produced by reaction with a linking reagent. In this embodiment, the core
functionality A is most preferably an alkene. It is well known that (E) olefin isoteres have been shown to be useful replacements for the amide linkage in drug candidates because the (E)-CR=CH group closely approximates the bond lengths, angles, and rigidities of the natural parent amide. However, as discussed above, the ability to generate compounds that do not necessarily mimic the structural properties of peptides, such as the (Z) olefin generated in the present system, constitutes an additional advantage of the present invention because it permits further investigation into unknown interactions between molecules and cellular receptors.
The structure depicted in Scheme 4 is available for randomization and diversification at several sites, allowing for the rapid synthesis of a library of compounds capable of emulating peptidic functions and structures, although these compounds are not necessarily required to emulate peptidic structure. For example, diversification can be achieved through functionalization at the R groups, represented by R,, R2 and R3 as shown in Scheme 4. At such sites, various functionalities can be substituted including but not limited to hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene cyclohexyl, benzyl, heteroaryl, aryloxy. carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio, and hydroxyl.
Alternatively or additionally, the segment unit replacement, represented by A, may be diversified. For example, instead of utilizing olefin metathesis to yield a double bond motif, a 2 + 2 addition to yield a cyclobutane segment unit can be initiated by photolysis (Figure 21 ) or by the use of certain transition metal catalysts such as Ti(CH2Ph) . This segment unit can then be further diversified by cyclobutane ring opening reactions including but not limited to reactions with cuprates, radical type fragmentations and DeMayo fragmentations. Alternatively, the double bond product can be converted into a cyclopropane (Figure 23) which also can be further diversified by reaction with a variety of nucleophiles, such as cuprates or organometallics. Additional diversification of the double bond may be achieved by hydrogenation, epoxidation, or dihydroxylation.
Although Scheme 4 depicts linked monomers, one of ordinary skill in the art will realize that the present discussion of the diversification of A can be extended to other embodiments where the monomers are reacted intermolecularly. In such embodiments, the diversification of the segment unit A is achieved through palladium coupling reactions
(Figure 4), Pinacol couplings (Figure 5), tandem aldol reactions/Curtius rearrangements (Figure 6) hydrozirconations (Figure 1), nucleophilic additions (Figure 8), and NHK couplings (Figure 9). The segment unit A also includes but is not limited to cyclobutane, cyclopropane, alkene, alkane, heteroatom, alkyne and aromatic functionalities. In another preferred embodiment of the present invention, the linking group can be removed to yield further diversifiable functionalities X, and X2, as shown in Scheme 5. These linking groups are preferably carbon, oxygen, sulfur or nitrogen containing functionalities such as hydroxy, thiol, or amine functionalities, which are capable of further reaction with electrophiles. In one example, the hydroxyl group depicted in Figure 24 is selectively protected via the Hoffman Rearrangement. Preferably Lu and L22 each comprise the same or different terminal reactive moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic, aldehyde and vinyl halide; Rb R2 and R3 are preferably selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene cyclohexyl, benzyl, heteroaryl, aryloxy, heteroaryl, carboxyl, carboxalkyl. carboxaryl, arylalkyl, thio and hydroxyl; X3 and X4 each preferably comprises a functional moiety selected from the group consisting of carboxyl, amino, gem-dialkyl, and methylene; and X, and X2 preferably each comprise a functionality containing nitrogen, oxygen, sulfur or carbon. In this embodiment, the core functionality A is most preferably an alkene.
Scheme 5
Combinatorial Methods
As mentioned above, the monomers may be diversified prior to or after reaction to generate core structures. Additionally, after their synthesis, the core structures can also be diversified. As will be appreciated by one of ordinary skill in the art, the synthesis of libraries from the above-described core structures and monomers can be performed using established combinatorial methods for solution phase, solid phase, or a combination of solution phase and solid phase synthesis techniques. The synthesis of combinatorial libraries is well known in the art and has been reviewed (see, e.g., "Combinatorial Chemistry", Chemical and Engineering News, Feb. 24, 1997, p. 43; Thompson, L.A., Ellman, J.A., Chem. Rev. 1996, 96, 555.) One of ordinary skill in the art will realize that the choice of method will depend upon the specific number of compounds to be synthesized, the specific reaction chemistry, and the availability of specific instrumentation, such as robotic instrumentation for the preparation and analysis of the inventive libraries. In particularly preferred embodiments, the reactions to be performed on the monomers and core structures to generate the libraries are selected for their ability to proceed in high yield, and in a stereoselective fashion
In one embodiment of the present invention, the inventive libraries are generated using a solution phase technique. Traditional advantages of solution phase techniques for the synthesis of combinatorial libraries include the availability of a much wider range of organic reactions, and the relative ease with which products can be characterized. Notable disadvantages of solution phase techniques includes the inability to easily synthesize libraries of compounds containing very large numbers, such as one million or more library members, because one reaction vessel must be provided for each library member, and the inability to use excess reagents without time-consuming purification steps, such as chromatography. Recently, however, advances have been made in solution phase synthesis techniques such as the use of a "covalent scavenger" which selectively removes from solution via covalent bond formation. The "covalent scavenger" is essentially a solid phase bound nucleophile or electrophile that reacts with these excess reagents. (Kaldor, Eli Lilly, Frechet et al., Tetrahedron Lett., 21, 617 (1980)). In a preferred embodiment, for the generation of a solution phase combinatorial library, a parallel synthesis technique is
utilized, in which all of the products are assembled separately in their own reaction vessels. In a particularly preferred parallel synthesis procedure, a microtitre plate containing n rows and m columns of tiny wells which are capable of holding a few milliliters of the solvent in which the reaction will occur, is utilized. It is possible to then use n variants of reactant A, such as a carboxylic acid, and m variants of reactant B, such as an amide to obtain n x m variants, in n x m wells. One of ordinary skill in the art will realize that this particular procedure is most useful when smaller libraries are desired, and the specific wells can provide a ready means to identify the library members in a particular well.
In another more particularly preferred embodiment of the present invention, a solid phase synthesis technique is utilized, in which the desired scaffold structures are attached to the solid phase directly or though a linking unit, as discussed above. Advantages of solid phase techniques include the ability to more easily conduct multi-step reactions and the ability to drive reactions to completion because excess reagents can be utilized and the un reacted reagent washed away. Perhaps one of the most significant advantages of solid phase synthesis is the ability to use a technique called "split and pool", in addition to the parallel synthesis technique, developed by Furka. (Furka et al., Abstr. 14th Int. Congr. Biochem., Prague, Czechoslovakia, 1988, 5. 47, Furka et al.. Int. J. Pept. Protein Res. 1991. 3". 487; Sebestyen et al., Bioorg. Med. Chem. Lett., 1993, 3, 413.) In this technique, a mixture of related compounds can be made in the same reaction vessel, thus substantially reducing the number of containers required for the synthesis of very large libraries, such as those containing as many as or more than one million library members. As an example, the core structures or monomers can be divided into n vessels, where n represents the number species of reagent A to be reacted with the core structures or monomers After reaction, the contents from n vessels are combined and then split into m vessels, where m represents the number of species of reagent B to be reacted with the core structures or monomers. This procedure is repeated until the desired number of reagents is reacted with the core structures or monomers to yield the inventive library.
The use of solid phase techniques in the present invention may also include the use of a specific encoding technique. Specific encoding techniques have been reviewed by Czarnik. (Czarnik, A.W., Current Opinion in Chemical Biology, 1997, 1, 60.) As used in
the present invention, an encoding technique involves the use of a particular ' identifying agent attached to the solid support, which enables the determination of the structure of a specific library member without reference to its spatial coordinates One of ordinary skill in the art will also realize that if smaller solid phase libraries are generated in specific ieaction wells, such as 96 well plates, or on plastic pins, the reaction history of these library members may also be identified by their spatial coordinates in the particular plate, and thus are spatially encoded It is most preferred, however for large combinatorial libraries, to use an alternative encoding technique to record the specific reaction history
Examples of particular preferred alternative encoding techniques that can be utilized in the present invention include, but are not limited to, spatial encoding techniques, graphical encoding techniques, including the "tea bag" method, chemical encoding methods, and spectrophotometπc encoding methods Spatial encoding refers to recording a reaction's history based on its location Graphical encoding techniques involve the coding of each svnthesis platform to permit the generation of a relational database Examples of preferred spectrophotometπc encoding methods include the use of mass spectroscopy, fluorescence emission, and nuclear magnetic resonance spectroscopy In a most preferred embodiment, chemical encoding methods are utilized, which uses the structure of the reaction product to code for its identity Decoding using this method can be performed on the solid phase or off of the solid phase One of ordinary skill in the art will realize that the particular encoding method to be used in the present invention must be selected based upon the number of library members desired, and the reaction chemistry employed
Peptide Morphing
As mentioned above, one particular aspect of the present invention is the provision of methods and reagents for preparing and identifying chemical compounds that mimic certain desired structural and/or functional properties of a predetermined peptide For example, a variety of techniques (e g , alanine scanning mutagenesis, NMR, X-ray crystallography, etc ) are available for defining within a biologically active protein particular peptide sequences, or dispersed amino acids or small collections of amino acids,
that are responsible for part or all of the protein's function Once such an active sequence is defined, the present invention provides a novel approach for preparing a non-peptide compound that captures the functionality of that sequence
In particular, the methods discussed above provide libraries of chemical compounds that typically resemble of di- or tn-peptide moieties As discussed above, the libraries can be prepared in the context of an existing peptide structure, that functions as a biasing element for the library, or can be embedded within a peptide after their preparation
Thus, the techniques described herein allow preparation of a library of peptide derivatives corresponding to a known active sequence except that two or three residues of the sequence are replaced with an inventive library This peptide derivative library can readilv be screened to identify those compounds within it that retain the peptide activity of interest In this way, a portion of the peptide is "morphed" into another compound that retains the peptide activity
This morphing method is not limited to substitution of a single di- or tn-peptide unit within an active sequence Once one unit has been morphed, a second unit within the peptide can be subjected to the same procedure, and so on Alternatively, two or more units may be morphed simultaneously As yet another alternative, two or more units may be morphed in parallel and the final morphed structures may subsequently be embedded within a single peptide Once a portion of an active sequence has been successfully morphed, it may be possible to remove some or all remaining peptide sequence without destroying the peptide-like activity of the compound Another way of removing all peptide components from an active sequence, of course, is to morph the entire sequence
Uses
The method, compounds, and libraries of the present invention can be utilized in various disciplines Any available method may be employed to screen the libraries produced according to the present invention to identify those with desirable characteristics for a selected application
To give just a few examples, the present invention can be utilized to produce peptidomimetic compounds that control (i.e., promote or inhibit) cell functions. Such compounds may be formulated and utilized as therapeutic pharmaceuticals. For example, such therapeutic pharmaceuticals, through interactions with cellular receptors, can control HIV production, cell proliferation, viral replication, gene expression, or any other cell signaling process. For example, a morphed segment produced according to the present invention can be embedded in a SH2 binding peptide, as shown in Figure 25. Figure 26 depicts model studies showing the binding of a morphed peptide to a SH2 domain. In another example, a library of inhibitors of DNA Glycosylases as shown in Figure 27 can be synthesized according to the method of the present invention. Additionally, a library of synthetic transcriptional regulators can be developed by the attachment of FK506 to the resin linked library of the present invention via an olefin linker as depicted in Figure 28. Furthermore, Figure 29 depicts a use for the inventive compounds and libraries in the E6 E6-.AP system. Figure 30 depicts a use for the inventive compounds and libraries in the renin-angiotensin system. Finally, Figure 3 1 depicts a use for the inventive compounds and libraries as inhibitors of the proteasome.
Inventive peptidomimetic or stereodiverse compounds can alternatively or additionally be used for catalysis, either as a ligand for a transition metal capable of mimicking an important biological environment, or by acting in concert with a particular transition metal catalyst to effect a particular desired enantioselective chemical reaction.
Inventive peptidomimetic or stereodiverse compounds are also useful in the area of materials science. Because of the reactive moieties present at the terminal ends of these compounds, molecules such as lipids and other polymeric molecules may be attached and thus generate potentially important biomaterials. It will be appreciated by one of ordinary skill in the art that the present invention is not intended to be limited to the abovementioned uses, but rather may be employed in many contexts and disciplines.
Examples
Example 1:
Norephedrine (compound 1) was purchased from Aldrich (28,255-3, 31,750-0, both enantiomers available) and used as received. Norephedrine (32 g, 21 1 mmoles) was placed in a flame-dried 250 ml round bottom flask equipped with a stir bar. Diethyl carbonate (60 ml, 422 mmoles) (Aldrich D9.155-1) and K2CO3 (2.5 g, 21 mmoles) were added and the resulting slurry was heated to 120°C under a Dean-Stark trap for 16 hours. After that time, the reaction mixture was diluted with methylene chloride and water and extracted (3X) with 300 ml of methylene chloride, dried with anhydrous MgSO4, filtered and concentrated under vacuum. Compound 2 was recrystallized from 1 :2 EtOAc/Hexanes. Yield: 34 g (91%).
Example 2:
Compound 2 (8.9 g, 50 mmoles) was placed in a 500 ml round bottom flame-dried flask equipped with a stir bar and then dissolved in 150 ml THF. The solution was then cooled to -78 ° C and to this solution was added dropwise over a period of five minutes 1.6 ml (50.5 mmoles) of 1.6 M solution of n-BuLi in hexanes (Aldrich 18,617-1). Upon complete addition, 4-methylvaleroyl chloride (Pfaltz & Bauer M30370) was added via syringe. The solution was stirred at -78 °C for 30 minutes and then allowed to warm up to room temperature over 15 minutes. At this time, 100 ml of saturated NH4C1 was added. The organic solvent was removed under vacuum and the remaining slurry was then extracted (3X) with 250 ml of methylene chloride, dried with anhydrous MgSO , filtered and concentrated under vacuum. Yield: 14.4 g (105%). Compound 3 was used in the next step without further purification.
Example 3:
To a solution of compound 3 (15.4 g, 50 mmol) in 200 ml of methylene chloride cooled down to 0°C were added dropwise 55.0 ml of 1.0 M solution of dibutylboron triflate in methylene chloride (Aldrich 26, 147-5) and redistilled diisopropylamine (10.5 ml, 60 mmol) at a rate such that the internal temperature did not exceed 3.0°C. The resulting
clear, colorless solution was cooled down to -78 °C and acrolein (16 7 ml, 250 mmol, Aldrich 1 1,022-1), dried by pouring through a short plug of neutral aluminum oxide immediately before use) was then added via syringe over a period of five minutes After stirring for 60 minutes at -78 °C, the reaction was quenched by adding 200 ml of 5 1 MeOH/H2O2, which was precooled to 0°C, and stirred for another 10 minutes at -78 °C and then 30 minutes at 0°C The reaction volume was reduced by removing the organic solvents under vacuum, 300 ml of methylene chloride and 300 ml of 5% NaHCO3 were added and the product was extracted (3X with methylene chloride, dried with anhydrous MgSO4. filtered and concentrated under vacuum Yield 22 0 g (133 %) The crude compound 4 was used in the next step without further purification
Example 4:
In a flame-dried round bottom flask equipped with a stir bar, benzylmercaptane (11 3 ml 1 0 mmol, Aldrich B2,540-l) was dissolved in 75 ml of THF and the solution va cooled tc 0°C and 1 6 M solution of n-BuLi in hexanes (62 5 ml, Aldrich 18,617- 1) was added dropwise over a period of five minutes To that solution, 2 0 M solution of AlMe in toluene (50 0 ml Aldrich 19,804-8 ) was added dropwise over a period of five minutes The reaction was allowed to stir for an additional 30 minutes at 0°C and the solution of BnSAlMe3Lι was added dropwise via cannula The reaction was stirred for 120 minutes at 0°C, carefully quenched with 200 ml of 1 0 M aqueous solution of HC1 (vigorous foaming) at 0°C and then stirred for an additional 30 minutes at room temperature The reaction was extracted (3X) with 200 ml of EtOAc, dried with anhydrous MgSO4, filtered and concentrated under vacuum Compounds 2 and 5 in the crude reaction mixture were separated by precipitating compound 13 from neat hexanes The hexane solution of compound 5 was concentrated under vacuum and purified by flash chromatography in 7 1 Hexanes/EtOAc + 0 2% MeOH Yield 8 0 g (58 % over the last three steps) Compound 2 was recrystalhzed from 1 2 hexanes/EtOAc Yield 6 1 g (68%)
Example 5:
In a 25 ml flame-dried round-bottom flask equipped with a stir bar, compound 5 (4 50 g, 16 mmol) was dissolved in 4 0 ml of DMF and to this solution was added TBDMSC1 (3 0 g, 20 mmoles, Aldrich 19,050-0) and imidazole (2 2 g, 32 mmoles, Aldrich 43,615-1) The reaction was allowed to stir for 14 hours at room temperature After this time, the reaction was quenched by the addition of 30 ml of satuiated aqueous NaHCO3 and extracted (3X) with methylene chloride, dried with anhydrous MgSO4, filtered and concentrated under vacuum Yield 6 9 g (1 10%) Compound 6 was used in the subsequent step without further purification
Example 6:
In a 500 ml round-bottom flask equipped with a stir bar, compound 6 (5 31 g; 13 mmoles) was dissolved in 160 ml of THF, 50 ml of MeOH and 50 ml H20 The solution was cooled down to 0°C and 1 2 g of LiOH and 9 0 ml of 30 % H2O2 was added, respectively The reaction was allowed to warm up to room temperatuie and, after 8 hours at room temperature, it was quenched by addition of 1 0 M aqueous solution of Na2SOt (156 ml Aldrich 20,784-5) at 0° C and stirred at room temperature for an additional 30 minutes The reaction was acidified to pH = 2 by adding 200 ml of 1 0 M KHSO4 (pH of the aqueous layer was checked by using pH paper strips) The reaction was extracted (3X) with methylene chloride, dried with anhydrous MgSO4, filtered and concentrated under vacuum Yield 4 8 g (105 %) Compound 7 was used in the subsequent step without further purification
Example 7:
REFERENCE Synthesis 131, (1989)
In a 250ml flame-dried round-bottom flask equipped with a stir bar, compound 7 (4 8g, 1 όmmoles) was dissolved in 80 ml of distilled acetonitπle To this solution, freshly
distilled TEA (2 5ml, 18 mmoles) was added followed by diphenylphosphoryl azide (3 8ml, 18 mmoles, Aldrich 17,875-6) A condenser was placed on the flask and the reaction was refluxed for 30 minutes at 85 °C The reaction was then cooled to room temperature and CuCl (0 4g, 4 mmoles, Aldrich 22,962-8) was added followed by 9-fluorenemethanol (9 4g, 48 mmoles, Aldrich 16,050-4) The reaction was stirred for additional 120 minutes at room temperature and quenched by addition of 100 ml of saturated NaHCO3 The reaction was extracted (3X) with EtOAc, dried with anhydrous MgSO4, filtered and concentrated under vacuum The crude product was purified by flash chromatography (19 1 hexanes/EtOAc +0 2%MeOH) Yield 3 6g (47%)
Example 8:
REFERENCE JACS 94, 6195, (1972)
In a 250ml round-bottom flask equipped with a stir bar, compound 8 (3 6g, 7 5 moles) was dissolved in 45 ml of AcOH, 15 ml of H2O and 15 ml of THF and stirred at 1 Cf C r 4 hi s After that time, the solvent was removed under vacuum by azeotropic distillation with toluene and the crude product was purified by flash chromatography (4 1 FIexanes EtOAcK) 2%MeOH) Yield 2 0 g (73%)
Example 9 REFERENCE JACS 113, 9661, (1991)
A 25ml flame-dried round bottom flask was charged with freshly distilled dimethyldichlorosilane (2 4 ml, 20 mmoles, Aldrich 44,027-2) and 5 ml of freshly distilled pyπdine were added In a separate flask, compound 5 (278 mg, 1 mmole) was dissolved in 2 0 ml of freshly distilled pyπdine and transferred via cannula to the solution of dimethyldichlorosilane in pyπdine The flask was then washed with another 0 5 ml of pyπdine and the reaction was stirred for 2 hrs at room temperature After that time, a short- path distillation head was placed on the flask and excess dichlorodimethylsilane and pyπdine were removed under high vacuum To the resulting slurry, compound 9 (365 mg, lmmole) dissolved in a separate flask in 9 ml of freshly distilled pyπdine was transferred
via cannula and the reaction was stirred for another 2 hours at room temperature The excess of pyridine was removed under high vacuum, 20 ml of saturated NaHC03 were added and the reaction was extracted (3X) with EtOAc, dried with anhydrous MgSO4, filtered and concentrated under vacuum The crude product was purified by flash chromatography (15 1 hexanes/EtOAc+0 2%MeOH) Yield 427 mg (61%)
Example 10:
A 25 ml flame-dried round-bottom flask was charged with compound 11 (427 mg, 0 61 mmoles) and 6 ml of distilled THF were added A reflux condenser was placed on the flask and the system was flushed with argon In a separate flask, the Grubbs' catalyst (255 mg, 0 31 mmoles, Strem 44-0065) was dissolved in 3 0 ml of freshly distilled methylene chloride and transferred via cannula to the flask containing compound 12 which was then heated to 40° for 24 hours After that time, another portion of the Grubbs' catalyst (255 mg, 0 31 mmoles dissolved in 3 0 ml of freshly distilled dichloromethane) was added via cannula and the heating was continued for another 24 hours The reaction was then concentrated under vacuum and purified by flash chromatography (12 1 hexanes/EtOAc+0 2% MeOH) Yield 1 16 mg (28%), recovered starting material 185 mg (43%) The recovered starting material was resubjected to the same metathesis conditions with the same percentage yield of the product Additionally, this metathesis reaction can be now carried out with 5% mol percent of the new catalyst (Grubbs et al , Tet. Lett., 1999, 40, 2247, Nolan et al , accepted for publication in J. Am. Chem. Soc.) This improved catalyst greatly increases the efficiency of the metathesis reaction
Example 11: In a 50 ml Corning plastic test tube, compound 11 (166 mg, 0 25 mmoles) was dissolved in 1 ml of THF and cooled down to 0°C A solution of HF in pyridine (71 ml, 2.5 mmoles, Aldrich 18,422-5) was added dropwise, the reaction was allowed to warm up to room temperature and stirred for additional 30 minutes at room temperature After that time, the reaction was carefully quenched with 10 ml of 1 0M Na2CO3 (vigorous foaming),
extracted (3X) with EtOAc, dried with anhydrous MgSO , filtered and concentrated under vacuum The crude product was purified by flash chromatography (3 1 hexanes/EtOAc+1 0% MeOH) Yield 85 mg (50%) Note The low yield is most likely caused by the residual catalyst decomposition products increasing the weight of compound 11 before the deprotection
Example 12:
In a 5 ml flame-dried pear-shaped flask, compound 12 (106 mg, 0 13 mmoles) was dissolved in 1 3 ml of THF To that solution, DIPEA (46 ml, 0 26 mmoles) and Hg(OCOCF3)2 ( 1 11 mg, 0 26 mmoles, Aldrich 15,648-5) were added, respectively and the resulting yellow solution was stirred for another 30 minutes at room temperature After that time, the reaction was concentrated under vacuum and the crude product (compound 13) purified by flash chromatography (1 1 hexanes EtOAc+ 1 0%MeOH) Yield 55 mg (65%)
Example 13:
REFERENCE JACS (1997), 119, 2586
Norephedrine (compound 1 ) was purchased from Aldrich (28,255-3, 31,750-0, both enantiomers available) and used as received Norephedrine (7 6g, 50 mmoles) was placed in a flame-dried 500ml round-bottom flask equipped with a stir bar, dissolved in 200 ml of freshly distilled methylene chloride and cooled down to 0°C Freshly distilled Et3N (8 3 ml, 60 mmoles) was added slowly over a period of 5 minutes and then 2-mesιtylenesulfonyl chloride (Aldrich M770-7, 11 0 g, 50 mmoles) dissolved in 25 ml of freshly distilled methylene chloride was added slowly via cannula over a period of 5 minutes The reaction mixture was allowed to warm to room temperature and stirred for another 4 hours After that time, the reaction mixture was extracted (3X) with EtOAc, dried with anhydrous
MgSO4, filtered and concentrated under vacuum The crude product (compound 14) was recrystallized from methylene chloride hexane Yield 15 7 g (94%)
Example 14:
REFERENCE JACS (1997), 119, 2586
Compound 14 (15 7g, 47 mmoles) was placed in a 500ml round-bottom flame-dπed flask equipped with a stir bar and then dissolved in 188 ml freshly distilled acetonitπle To that solution, K2CO3 (9 7 g, 71 mmoles) and benzyl bromide (Aldrich B 1,790-5, 6 8 ml, 56 mmoles) were added, respectively The flask was equipped with a reflux condenser and refluxed for 36 hours After that time, the reaction was quenched with 20 ml of saturated NH C1, extracted (3X) with EtOAc, dried with anhydrous MgSO4, filtered and concentrated under vacuum The crude product (compound 15) was purified by flash chromatography (6 1 -> 4 1 hexanes EtOAc + 0 2% MeOH gradient) Yield 17 7 g (89%)
Example 15:
REFERENCE JACS (1997), 119, 2586
Compound 15 (4 2g, 10 mmoles) was placed in a 200ml round-bottom flame-dried flask equipped with a stir bar, dissolved in 43 ml of freshly distilled methylene chloride and cooled down to 0°C Freshly distilled pyridine (1 1 ml, 13 mmoles) was dropwise and after 10 minutes 4-methylvaleroyl chloride (Pfaltz & Bauer M30370, 1 6 ml, 12 mmoles) was added dropwise via syringe The reaction was allowed to warm to room temperature and stirred for another 16 hours After that time, the reaction mixture was extracted (3X) with EtOAc, dried with anhydrous MgSO4, filtered and concentrated under vacuum The crude product (compound 16) was used in the subsequent step without further purification Yield 5 6 g (108%)
Example 16: REFERENCE JACS (1997), 119, 2586
Compound 16 (5 6g, 10 mmoles) was placed in a 250ml round-bottom flame-dried flask equipped with a stir bar, dissolved in 75 ml of freshly distilled methylene chloride and cooled down to 0°C and freshly distilled Et3N was added via syringe The reaction mixture
was cooled down to -78°C and a precooled 1 0 M solution of Cx2BOTf in methvlene chloride (20 ml, 20 mmoles - prepared as described in JOC (1992), 57, 499 and JOC (1993), 58, 147) was added slowly via cannula over a period of five minutes The reaction was stirred for additional 2 hours at -78°C after which time acrolein (0 8 ml, 12 mmoles, Aldrich 11,022-1, dried by pouring through a short plug of neutral aluminum oxide immediately before use) was added via syringe and the reaction was stirred for another hour at -78°C and then for another hour at 0°C After that time, the reaction was quenched by adding 40 ml of 1 0M phosphate buffer (pH=7 0), 100 ml of MeOH and 10 ml of 30%H2O2 and stirred for 1 hour at room temperature The quenched reaction was extracted (3X) with methvlene chloride, dried with anhydrous MgSO4, filtered and concentrated under vacuum The crude product (compound 17) was purified by flash chromatography in 6 1 hexanes EtOAc + 0 2 MeOH Yield 5 2 g (90%)
Example 17: REFERENCE TL (1986), 27, , 1735
Compound 17 (5 2 g, 9 mmoles) was placed in a 200 ml round-bottom flask and dissolved in 72 ml of methanol To that solution, NaOH (1 8 g, 45 mmoles) dissolved in 18 ml of water was added slowly and the resulting cloudy solution was stirred for additional 14 hours at room temperature After that time, methanol was removed on rotatory evaporator, 200 ml of water was added to the resulting slurry and the clear solution was extracted (3X) with EtOAc The organic layer was dried with anhydrous MgS0 , filtered and concentrated under vacuum The crude compound 15 was recrystalhzed from methylene chloride hexane Yield 3 4 g (90%>) The aqueous layer was acidified to pH^l by adding concentrated HC1 and extracted (3X) with EtOAc dried with anhydrous MgSO4, filtered and concentrated under vacuum Compound 18 was used in the subsequent step with further purification Yield 1 2 g (80%)
Example 18:
Compound 18 (1 2 g, 7 mmoles) was dissolved in 3 ml of freshly distilled
methylene chloride and benzylmercaptane (2.4 ml, 22 mmoles, Aldrich B2, 540-1) was added The solution was cooled down to 0°C and 1.0M solution of DCC in methylene chloride (7.9 ml, 7.9 mmoles, Aldrich 37,911-5) was added dropwise via syringe and stirred for another 5 minutes at 0°C. After that time, the reaction was warmed up to room temperature and stirred for additional 2 hours. The reaction mixture was then diluted with Et^O, filtered through a short plug of Celite and concentrated under vacuum. The crude product (compound 19) was purified by flash chromatography in 8: 1 hexanes:EtOAc + 0.2 MeOH Yield: 1.5 g (75%).
Claims
1. A method for generating a library of compounds having stereochemical diversity comprising: selecting desired synthetic precursors having a defined stereochemical relationship; reacting the synthetic precursors so that a compound having a specific stereochemistry is obtained; and repeating the steps of selecting and reacting until a desired library of compounds having stereochemical diversity is obtained.
2. The method of claim 1, further comprising the step of diversifying said synthetic precursors after the step of selecting desired synthetic precursors so that a chemical library having stereochemical and structural diversity is obtained.
3. The method of claim 1, further comprising a step of diversifying said compounds having a specific stereochemistry after the step of reacting the synthetic precursors so that a chemical library having stereochemical and structural diversity is obtained.
4. A library of more than one chemical compound, wherein each of said more than one compounds comprises the same structural formula, and wherein each of said more than one compounds has a unique stereochemistry.
5. A library of chemical compounds, wherein said library comprises more than one compound having a unique structural formula, and wherein each of said compounds having a unique structural formula additionally comprises one or more compounds has a unique stereochemistry.
6. The library of claim 4 or claim 5 having the following structure:
wherein Lπ and L22 each comprise the same or different moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic, aldehyde, and vinyl halide; R,, R2 and R3 are functional moieties selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene, cyclohexyl, benzyl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl; wherein X, and X2 each independently comprise a carbon, nitrogen, oxygen or sulfur containing functionality, wherein X3 and X4 are each independently selected from the group consisting of carboxyl, amino, gem-dialkyl, amide, ester, thioester and methylene; and wherein A comprises a diversifiable segment unit.
7. The library of claim 6, wherein each of said compounds in said library is further attached, through one or more reactive terminal moieties, to another moiety selected from the group consisting of solid support unit, biomolecule, and polymer.
8. The library of claim 4 or claim 5 having the following structure:
wherein Ln and L22 each comprise the same or different moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic, aldehyde, and vinyl halide, R,, R2 and R3 are functional moieties selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene, cyclohexyl, benzyl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl; wherein X, and X2 each independently comprise a carbon, nitrogen, oxygen or sulfur functionality; wherein X3 and X4 are each independently selected from the group consisting of carboxyl. amino, gem-dialkyl. amide, ester, thioester and methylene; wherein L comprises a group, including but not limited to mixed carbonates (R and R'), carbamates, disulfides, ureas, acetals, ortho esters, phosphates and oxides, produced by reaction with a linking reagent; and wherein A comprises a diversifiable segment unit.
9. The library of claim 8, wherein each of said compounds in said library is further attached, through one or more reactive terminal moieties, to another moiety selected from the group consisting of solid support unit, biomolecule, and polymer
10. The library of claim 4 or claim 5 having the following structure:
Ri R2 R, R2 wherein Lu , L12 , L21 and L22 each comprise the same or different moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic, aldehyde, vinyl halide, biomolecule, and solid support unit; R R2 and R3 are functional moieties selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene, cyclohexyl, benzyl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl; wherein X, and X2 each independently comprise a carbon, nitrogen, oxygen or sulfur functionality; wherein X3 and X4 are each independently selected from the group consisting of carboxyl, amino, gem- dialkyl, amide, ester, thioester and methylene; and wherein L comprises a group produced by a reaction with a linking reagent.
1 1. The library of claim 10, wherein each of said compounds in said library is further attached, through one or more reactive terminal moieties, to another moiety selected from the group consisting of solid support unit, biomolecule, and polymer
12. The library of 10, wherein the linking reagent used to generate the linking group L is selected from the group consisting of dimethyldichlorosilane, diisopropylamino chlorophosphoramidite, sulfonyl chloride, and reagents containing a boron or titanium atom.
13. The library of claim 4 or claim 5 having the following structure:
wherein Lπ and L22 each comprise the same or different moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic, aldehyde, and vinyl halide; R,, R2 and R3 are functional moieties selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene, cyclohexyl, benzyl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl; wherein X, and X2 each independently comprise a carbon, nitrogen, oxygen or sulfur containing functionality; wherein X3 is selected from the group consisting of carboxyl, amino, gem-dialkyl, amide, ester, thioester and methylene; and wherein A comprises a diversifiable segment unit.
14. The library of claim 13, wherein each of said compounds in said library is further attached, through a reactive terminal moiety, to another moiety selected from the group consisting of solid support unit, biomolecule, and polymer.
15. The library of claim 4 or claim 5 having the following structure:
wherein Ln , L12, and L22 each comprise the same or different moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic, aldehyde, vinyl halide, biomolecule, and solid support unit; K R2 and R3 are functional moieties selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene, cyclohexyl, benzyl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl; wherein X, and X2 each independently comprise a carbon, nitrogen, oxygen or sulfur functionality; wherein X3 is selected from the group consisting of carboxyl, amino, gem-dialkyl, amide, ester, thioester and methylene; and wherein L comprises a group, including but not limited to mixed carbonates (R and R'), carbamates, disulfides, ureas, acetals, ortho esters, phosphates and oxides, produced by reaction with a linking reagent.
16. The library of claim 15 wherein each of said compounds in said library is further attached, through one or more reactive terminal moieties, to another moiety selected from the group consisting of solid support unit, biomolecule, and polymer.
17. The library of claim 4 or claim 5 having the following structure:
wherein L,, comprises a moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic, aldehyde, and vinyl halide; R,, R2 and R3 are functional moieties selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene, cyclohexyl, benzyl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl; wherein Xj and X2 each independently comprise a carbon, nitrogen, oxygen or sulfur functionality; wherein X3 is selected from the group consisting of carboxyl, amino, gem-dialkyl, amide, ester, thioester and methylene; wherein L comprises a group, including but not limited to mixed carbonates (R and R'), carbamates, disulfides, ureas, acetals, ortho esters, phosphates and oxides, produced by reaction with a linking reagent; and wherein A comprises a diversifiable segment unit.
18 The library of claim 17, wherein said linking reagent is selected from the group consisting of dimethyldichlorosilane, dnsopropylamino chlorphosphoramidite, sulfonyl chloride, and reagents containing a boron or titanium ion
19 The library of claim 17, wherein each of said compounds in said brarv is further attached, through one or more reactive terminal moieties, to another moiety selected from the group consisting of solid support unit, biomolecule, and polymer
20 The library of claim 4 or 5 having the following structure
wherein Ln comprises a moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic, aldehyde, and vinyl halide, R,, R2 and R3 are functional moieties selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene, cyclohexyl, benzyl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl, wherein X, and X2 each independently comprise a carbon, nitrogen, oxygen or sulfur functionality, wherein X, is selected from the group consisting of carboxyl, amino, gem-dialkyl, amide, ester, thioester and methylene, and wherein R4 comprises a group formed by reaction with a dipolarophile
21 The library of claim 20, wherein each of said compounds in said library is further attached, through one or more reactive terminal moieties, to another moiety selected from the group consisting of solid support unit, biomolecule, and polymer
22 The library of claim 4 or 5 having the following structure
wherein Lu comprises a moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic, aldehyde, and vinyl halide, R,, R2 and R3 are functional moieties selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene, cyclohexyl, benzyl, aryloxy, heteroaryl carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl, wherein X, comprises a carbon, nitrogen, oxygen or sulfur functionality, wherein X3 is selected from the group consisting of carboxyl, amino, gem-dialkyl, amide, ester, thioester and methylene, wherein A comprises a diversifiable segment unit, and wherein R comprises a group foimed by a hydrozirconation reaction
23 The library of claim 22, wherein each of said compounds in said library is further attached, through one or more reactive terminal moieties, to another moiety selected from the group consisting of solid support unit, biomolecule, and polymer
24 The library of claim 4 or 5 having the following structure
1 wherein Lu and L22 each comprise a moiety selected from the group consisting of
2 hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic,
3 aldehvde, and vinyl halide, R, and R2 are functional moieties selected from the group
4 consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene, cyclohexyl,
5 benzvl aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl,
6 wherein X, comprises a carbon, nitrogen, oxygen or sulfur functionality, wherein X3 and X
7 are each independently selected from the group consisting of carboxyl, amino gem-dialkyl,
8 amide ester, thioester and methylene, and wherein A comprises a diversifiable segment
9 unit
10
1 1 25 The library of claim 24, wherein each of said compounds in said library is further
12 attached through one or more reactive terminal moieties, to another moiety selected from the group consisting of solid support unit, biomolecule, and polymer ╬╣ 4
15 26 The library of claim 4 or 5 having the following structure
16
18 wherein Lu and L22 each comprise a moiety selected from the group consisting of
19 hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic, 0 aldehyde, and vinyl halide, Rt and R2 are functional moieties selected from the group 1 consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene, cyclohexyl, 2 benzyl aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl, 3 wherein X3 and X4 are each independently selected from the group consisting of carboxyl, 4 amino, gem-dialkyl, amide, ester, thioester and methylene, wherein A) comprises a 5 halogenated aromatic moiety, and wherein A2 comprises a diversifiable segment unit 6
27. The library of claim 25, wherein each of said compounds in said library is further attached, through one or more reactive terminal moieties, to another moiety selected from the group consisting of solid support unit, biomolecule, and polymer.
28 The library of claim 4 or claim 5 comprising at least 8 stereoisomers.
29 The library of claim 4 or claim 5 comprising at least 16 stereoisomers.
30. A method for generating one or more compounds having characteristics of peptides comprising: providing a first monomer, wherein said monomer is diversifiable and contains first and second terminal reactive moieties and at least one functionalizable group; providing a second monomer, wherein said second monomer is diversifiable and contains third and fourth terminal reactive moieties and at least one second functionalizable group, reacting said first monomer with said second monomer to yield a core structure in v/hich the monomers are attached to one another by way of the second and third terminal reactive moieties; and functionalizing said core structure.
31. The method of claim 30, wherein providing said first monomer and said second monomer comprises providing first and second monomers each having a desired stereochemistry, and wherein reacting said first monomer with said second monomer comprises subjecting said monomers to reaction conditions to effect a stereoselective reaction to obtain a core structure having desired stereochemistry.
32. The method of claim 30, further comprising attaching said first monomer to a solid 1 support to effect a solid phase synthesis of a core structure.
2
3 33. The method of claim 30, further comprising diversifying said first and second
4 monomers prior to reacting said first monomer with said second monomer.
5
6 34. The method of claim 30 wherein said first monomer and said second monomer are
7 reacted intermolecularly.
8
9 35. The method of claim 30, wherein said first monomer and said second monomer are
10 reacted intramolecularly.
1 1
12 36. The method of claim 0, wherein said fist and second monomers are attached to one
13 another intermolecularly or intramolecularly using an olefin metathesis reaction to generate 1 -1 a core structure in which the monomers are attached to one another by way of an alkenyl i 5 segment unit.
16
17 37. The method of claim 30, wherein said first monomer and said second monomer are
18 each independently selected from the group consisting of allylic alcohols, allylic thiols, 9 allylic amines, homoallylic alcohols, homoallylic thiols and homoallylic amines. 0 1
38. The method of claim 30, wherein said first monomer comprises the following 2 structure: 3
wherein Lu and LI2 each comprise the same or different terminal reactive moietv selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic, aldehyde and vinyl halide, R,, R2 and R3 are functional moieties selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methvlene, cyclohexyl, benzyl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl, wherein X comprises a functional moiety selected from the group consisting of carboxyl, amino, gem-dialkyl, and methylene. and wherein X, comprises a carbon, nitrogen, oxygen or sulfur containing functionality
39 The method of claim 30, wherein said second monomer comprises the following structure
wherein L21 and L22 each comprise the same or different terminal reactive moietv selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine. carboxylic acid, halogenated aromatic, aldehyde and vinyl halide, Rb R2 and R3 are functional moieties selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene, cyclohexyl, benzyl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl, wherein X comprises a functional moiety selected from the group consisting of carboxyl, amino, gem-dialkyl, and methylene, and wherein X2 comprises a carbon, nitrogen, oxygen or sulfur functionality
40 The method of claim 30, wherein said second monomer comprises the following structure
wherein L2, and L22 each comprise the same or different terminal reactive moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic, aldehyde and vinyl halide; R3 is a functional moiety selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide. methylene, cyclohexyl, benzyl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl; wherein X comprises a functional moiety selected from the group consisting of carboxyl, amino, gem-dialkyl, and methylene; and wherein X2 comprises a carbon, nitrogen, oxygen or sulfur functionality.
41. The method of claim 30, wherein at least 1,000 peptidomimetic compounds are generated.
42. The method of claim 30, wherein between 10,000 and 10,000,000 peptidomimetic compounds are generated.
43. A. method for generating one or more compounds having characteristics of peptides comprising: providing a monomer, wherein said monomer is diversifiable and contains first and second terminal reactive moieties and at least one functionalizable group; reacting said monomer with a chemical reagent to yield a diversifiable core structure in which terminal functionality is available for further diversification; and functionalizing said core structure.
44 The method of claim 43, wherein providing said monomer comprises providing a monomer having a desired stereochemistry, and wherein reacting said monomer with a chemical reagent comprises subjecting said monomer and chemical reagent to reaction conditions to effect a stereoselective reaction to obtain a core structure having desired stereochemistry
45 The method of claim 43, further comprising attaching said monomer to a solid support to effect a solid phase synthesis of a core structure
46 The method of claim 43, wherein said monomer is selected from the group consisting of allylic alcohols, allylic thiols, allylic amines, homoallylic alcohols, homoallylic thiols and homoallylic amines
47 The method of claim 43, wherein said monomer comprises the following structure
wherein Ln and LI2 each comprise the same or different terminal reactive moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic, aldehyde and vinyl halide, Rb R2 and R3 are functional moieties selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene, cyclohexyl, benzyl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl, wherein X comprises a functional moiety selected from the group consisting of carboxyl, amino, gem-dialkyl, and methylene; and wherein X, comprises a carbon, nitrogen, oxygen or sulfur containing functionality
48 The method of claim 43, wherein said chemical reagent comprises a dipolarophile
49 The method of claim 43, wherein at least 1,000 peptidomimetic compounds are generated
50 The method of claim 43, wherein between 10,000 and 10,000,000 peptidomimetic compounds are generated
51 A compound with a reactive moiety L, having the structure
wherein Lπ and L12 each comprise the same or different terminal reactive moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic, aldehyde and vinyl halide, R R2 and R3 are selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene cyclohexyl, benzyl, heteroaryl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl; wherein X comprises a functional moiety selected from the group consisting of carboxyl, amino, gem-dialkyl, and methylene; wherein X, comprises a functionality containing nitrogen, oxygen, sulfur or carbon; and wherein L comprises a group, including but not limited to mixed carbonates (R and R'), carbamates, disulfides, ureas, acetals, ortho esters, phosphates and oxides, produced by reaction with a linking reagent
52. The compound of claim 51 wherein the linking reagent used to generate the linking group L is selected from the group consisting of dimethyldichlorosilane, diisopropylamino chlorophosphoramidite, sulfonyl chloride, and reagents containing a boron or titanium atom.
53. The compound of claim 51, wherein said compound is further attached, through a reactive terminal moieties, to another moiety selected from the group consisting of solid support unit, biomolecule, and polymer.
54. A library of compounds having the following structure:
wherein Ln and L12 each comprise the same or different terminal reactive moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic, aldehyde and vinyl halide; Rb R2 and R3 are selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene cyclohexyl, benzyl, heteroaryl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl; wherein X comprises a functional moiety selected from the group consisting of carboxyl, amino, gem-dialkyl, and methylene; wherein Xj comprises a functionality containing nitrogen, oxygen, sulfur or carbon; and wherein L comprises a group, including but not limited to mixed carbonates (R and R'), carbamates, disulfides, ureas, acetals, ortho esters, phosphates and oxides, produced by reaction with a linking reagent.
55 The library of claim 54, wherein said linking reagent is selected from the group consisting of diisopropylamino chlorophosphoramidite, dimethyldichlorosilane, sulfonyl chloride, and reagents containing a boron or titanium atom
56 The library of claim 54 wherein each of said compounds in said library is further attached, through one or more reactive terminal moieties, to another moiety selected from the group consisting of solid support unit, biomolecule, and polymer.
57 A diversifiable core compound having the following structure
wherein Lu. Ln, L21, and L22 each comprise the same or different terminal reactive moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxviic acid, halogenated aromatic, aldehyde and vinyl halide, wherein Rb R2 and R3 are selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene cyclohexyl, benzyl, heteroaryl, aryloxy, carboxyl, carboxalkyl, carboxaryl, arylalkyl. thio and hydroxyl; wherein X! and X2 each comprise a functionality containing a carbon, nitrogen, oxygen or sulfur atom; wherein X and X4 each comprise the same or different functional group selected from the group consisting of carboxyl, amino, gem- dialkyl, and methylene; and wherein L comprises a group, including but not limited to mixed carbonates (R and R'), carbamates, disulfides, ureas, acetals, ortho esters, phosphates and oxides, produced by reaction with a linking reagent
58 The compound of claim 57, wherein the linking reagent is selected from the group consisting of dnspropylamino chlorophosphoramidite, dimethyldichlorosilane, sulfonyl chloride, and metal reagents containing a boron or titanium atom
59 The compound of claim 57, wherein said compound is further attached, through a reactive terminal moieties, to another moiety selected from the group consisting of solid support unit, biomolecule, and polymer
60 A library of compounds having the following structure
wherein Lπ, L12, L2b and L22 each comprise the same or different terminal reactive moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxviic acid, halogenated aromatic, aldehyde and vinyl halide, wherein Rb R2 and R3 are selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene cyclohexyl, benzyl, heteroaryl, aryloxy, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl, wherein Xj and X2 each comprise a functionality containing a carbon nitrogen, oxygen or sulfur atom, wherein X3 and X4 each comprise the same or different functional group selected from the group consisting of carboxyl, amino, gem- dialkyl, and methylene, and wherein L comprises a group, including but not limited to mixed carbonates (R and R'), carbamates, disulfides, ureas, acetals, ortho esters, phosphates and oxides, produced by reaction with a linking reagent
61 The library of claim 60 wherein said linking reagent is selected from the group consisting of dimethyldichlorosilane, dnsopropylamino chlorophosphoramidite, sulfonyl chloride, and reagents containing a boron or titanium atom
62 The library of claim 60, wherein each of said compounds in said library is further attached, through one or more reactive terminal moieties, to another moiety selected from the group consisting of solid support unit, biomolecule, and polymer
63 A. diversifiable core compound having the following structure
wherein Lu and L22 each comprise the same or different terminal reactive moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic, aldehyde, and vinyl halide, wherein R R2 and R3 are selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene cyclohexyl, benzyl, heteroaryl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl, wherein X, and X2 each comprise a functionality which contains at least a carbon, nitrogen, sulfur or oxygen atom, wherein X3 and X each comprise a functional moiety selected from the group consisting of carboxyl, am o, gem- dialkyl, and methylene, wherein A is a diversifiable segment unit, and wherein L comprises a group, including but not limited to mixed carbonates (R and R'), carbamates, disulfides, ureas, acetals, ortho esters, phosphates and oxides, produced by reaction with a linking reagent
64. The compound of claim 63, wherein said linking reagent is selected from the group consisting of dimethyldichlorosilane, diisopropylamino chlorphosphoramidite, sulfonyl chloride, and reagents containing a boron or titanium atom.
65. The compound of claim 63, wherein A comprises a double bond, and wherein the double bond is further functionalized using a reaction selected from the group consisting of hydrogenation, epoxidation, cyclopropanation, dihydroxylation, and cycloaddition.
66. The compound of claim 63, wherein said compound is further attached, through a reactive terminal moieties, to another moiety selected from the group consisting of solid support unit, biomolecule, and polymer.
67. A library of compounds having the following structure:
wherein Lu and L22 each comprise the same or different terminal reactive moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine. carboxylic acid, halogenated aromatic, aldehyde, and vinyl halide; wherein Rb R2 and R3 are selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene cyclohexyl, benzyl, heteroaryl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl; wherein Xi and X2 each comprise a functionality which contains at least a carbon, nitrogen, sulfur or oxygen atom; wherein X3 and X4 each comprise a functional moiety selected from the group consisting of carboxyl, amino, gem- dialkvl, and methvlene, wherein A comprises a diversifiable segment unit, and wherein L comprises a group, including but not limited to mixed carbonates (R and R'), carbamates, disulfides, ureas, acetals, ortho esters, phosphates and oxides, produced by reaction with a linking reagent
68 The library of claim 67, wherein said linking reagent is selected from the group consisting of dimethyldichlorosilane, dnsopropylamino chlorphosphoramidite, sulfonyl chloride, and metal reagents containing a boron or titanium atom
69 The library of claim 67, wherein A comprises a double bond, and said double bond is further functionalized using a reaction selected from the group consisting of hydrogenation, epoxidation, cyclopropanation, dihydroxylation and cycloaddition
70 The library of claim 67, wherein each of said compounds in said library is further attached, through one or more reactive terminal moieties, to another moiety selected from the group consisting of solid support unit, biomolecule, and polymer
71 The compound of claim 64 or the library of claim 67, wherein the diversifiable core functional unit A is selected from the group consisting of cyclobutane, cyclopropane, alkene alkane, heteroaryl, heteroatom, alkyne and aromatic
72 A diversifiable core compound having the following structure
wherein Lu and L22 each comprise the same or different terminal reactive moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic, aldehyde, and vinyl halide, wherein Rb R2 and R3 are selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene cyclohexyl, benzyl, heteroaryl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl, wherein X, and X2 each comprise a functionality which contains at least a carbon, nitrogen, sulfur or oxygen atom, wherein X3 and X4 each comprise a functional moiety selected from the group consisting of carboxyl, amino, gem- dialkvl, and methylene, and wherein A comprises a diversifiable segment unit
73 The core molecule of claim 72, wherein A comprises a double bond, and wherein the double bond is further functionalized by employing a reaction selected from the group consisting of hydrogenation, epoxidation, cyclopropanation, dihydroxylation, and cycloaddition
74 The compound of claim 72, wherein said compound is further attached, through a reactive terminal moiety, to another moiety selected from the group consisting of solid support unit, biomolecule, and polymer
75 A library of core compounds having the following structure
wherein Lπ and L22 each comprise the same or different terminal reactive moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic, aldehyde, and vinyl halide; wherein R R2 and R3 are selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene cyclohexyl, benzyl, heteroaryl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl; wherein X, and X2 each comprise a functionality which contains at least a carbon, nitrogen, sulfur or oxygen atom; wherein X3 and X4 each comprise a functional moiety selected from the group consisting of carboxyl, amino, gem- dialkyl, and methylene; and wherein A comprises a diversifiable segment unit.
76. The library of claim 75, wherein A comprises a double bond, and wherein the double bond is further functionalized by employing a reaction selected from the group consisting of hydrogenation, epoxidation, cyclopropanation, dihydroxylation, and cycloaddition.
77. The library of claim 75, wherein each of said compounds is further attached. through one or more reactive terminal moieties, to another moiety selected from the group consisting of solid support unit, biomolecule, and polymer.
78 A core compound having the following structure:
wherein Lu and L22 each comprise the same or different terminal reactive moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic, aldehyde, and vinyl halide; wherein R R2 and R3 are selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene cyclohexyl, benzyl, heteroaryl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl; wherein X, and X2 each comprise a functionality which contains at least a carbon, nitrogen, sulfur or oxygen atom; wherein X3 comprises a functional moiety selected from the group consisting of carboxyl, amino, gem-dialkyl, and methylene; and wherein A comprises a diversifiable segment unit.
79. The core molecule of claim 78, wherein A comprises a double bond, and wherein the double bond is further functionalized by employing a reaction selected from the group consisting of hydrogenation, epoxidation, cyclopropanation, dihydroxylation, and cycloaddition.
80. The compound of claim 78, wherein said compound is further attached, through a reactive terminal moieties, to another moiety selected from the group consisting of solid support unit, biomolecule, and polymer.
81. A library of core compounds having the following structure:
wherein Lu and L22 each comprise the same or different terminal reactive moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic, aldehyde, and vinyl halide; wherein R R2 and R3 are selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene cyclohexyl, benzyl, heteroaryl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl, wherein X, and X2 each comprise a functionality which contains at least a carbon, nitrogen, sulfur or oxygen atom, wherein X3 comprises a functional moiety selected from the group consisting of carboxyl, amino, gem-dialkyl, and methylene, and wherein A comprises a diversifiable segment unit
82 The library of claim 81, wherein A comprises a double bond, and wherein the double bond is further functionalized by employing a reaction selected from the group consisting of hydrogenation, epoxidation, cyclopropanation, dihydroxylation. and cycloaddition
83 The library of claim 81 , wherein each of said compounds is further attached, through one or more reactive terminal moieties, to another moiety selected from the group consisting of solid support unit, biomolecule, and polymer
84 A. core compound having the following structure
wherein L] L12, and L22 each comprise the same or different terminal reactive moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic, aldehyde, and vinyl halide, wherein R,, R2 and R3 are selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene cyclohexyl, benzyl, heteroaryl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl; wherein X, and X2 each comprise a functionality which contains at least a carbon, nitrogen, sulfur or oxygen atom; wherein X3 comprises a functional moiety selected from the group consisting of carboxyl, amino, gem-dialkyl, and methylene; and wherein L comprises a group, including but not limited to mixed carbonates (R and R'), carbamates, disulfides, ureas, acetals, ortho esters, phosphates and oxides, produced by reaction with a linking reagent.
85. The compound of claim 84, wherein said linking reagent is selected from the group consisting of dimethyldichlorosilane, diisopropylamino chlorphosphoramidite. sulfonyl chloride, and reagents containing a boron or titanium atom.
86. The compound of claim 84, wherein said compound is further attached, through a reactive terminal moiety, to another moiety selected from the group consisting of solid support unit, biomolecule, and polymer
87. A library of core compounds having the following structure:
wherein Llb L12, and L22 each comprise the same or different terminal reactive moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic, aldehyde, and vinyl halide; wherein Rb R2 and R3 are selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene cyclohexyl, benzyl, heteroaryl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl; wherein X, and X2 each comprise a functionality which contains at least a carbon, nitrogen, sulfur or oxygen atom; wherein X3 comprises a functional moiety selected from the group consisting of carboxyl, amino, gem-dialkyl, and methylene; and wherein L comprises a group, including but not limited to mixed carbonates (R and R'), carbamates, disulfides, ureas, acetals, ortho esters, phosphates and oxides, produced by reaction with a linking reagent.
88. The library of claim 87, wherein said linking reagent is selected from the group consisting of dimethyldichlorosilane, diisopropylamino chlorphosphoramidite. sulfonyl chloride, and reagents containing a boron or titanium atom.
89. The library of claim 87, wherein said compound is further attached, through a reactive terminal moiety, to another moiety selected from the group consisting of solid support unit, biomolecule, and polymer.
90. A core compound having the following structure:
wherein Ln comprises a terminal reactive moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic, aldehvde, and vinyl halide, wherein Rb R2 and R3 are selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene cyclohexyl, benzyl, heteroaryl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl, wherein X, and X2 each comprise a functionality which contains at least a carbon, nitrogen, sulfur or oxygen atom, wherein X3 comprises a functional moietv selected from the group consisting of carboxyl, amino, gem-dialkyl, and methylene, wherein A is a diversifiable segment unit, and wherein L comprises a group, including but not limited to mixed carbonates (R and R'), carbamates, disulfides, ureas, acetals, ortho esters, phosphates and oxides, produced by reaction with a linking reagent
91 The compound of claim 90, wherein said linking reagent is selected from the group consisting of dimethyldichlorosilane, diisopropylamino chlorphosphoramidite, sulfonyl chloride, and reagents containing a boron or titanium atom
92 The compound of claim 90, wherein A comprises a double bond, and wherein the double oond is further functionalized using a reaction selected from the group consisting of hydrogenation, epoxidation, cyclopropanation, dihydroxylation, and cycloaddition
93 The compound of claim 90, wherein said compound is further attached, through a reactive terminal moiety, to another moiety selected from the group consisting of solid support unit, biomolecule, and polymer
94 A library of core compounds having the following structure
wherein Ln comprises a terminal reactive moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic, aldehyde, and vinyl halide; wherein R R2 and R3 are selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene cyclohexyl, benzyl, heteroaryl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl; wherein X, and X2 each comprise a functionality which contains at least a carbon, nitrogen, sulfur or oxygen atom; wherein X3 comprises a functional moiety selected from the group consisting of carboxyl, amino, gem-dialkyl, and methylene; wherein A is a diversifiable segment unit, and wherein L comprises a group, including but not limited to mixed carbonates (R and R'), carbamates, disulfides, ureas, acetals, ortho esters, phosphates and oxides, produced by reaction with a linking reagent.
95. The library of claim 94, wherein said linking reagent is selected from the group consisting of dimethyldichlorosilane, diisopropylamino chlorphosphoramidite. sulfonyl chloride, and reagents containing a boron or titanium atom.
96. The library of claim 94, wherein A comprises a double bond, and wherein the double bond is further functionalized using a reaction selected from the group consisting of hydrogenation, epoxidation, cyclopropanation, dihydroxylation, and cycloaddition.
97. The library of claim 94, wherein said compound is further attached, through a reactive terminal moieties, to another moiety selected from the group consisting of solid support unit, biomolecule, and polymer.
98. A core compound having the following structure:
wherein Lπ comprises a moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic, aldehyde, and vinyl halide, Rb R2 and R3 are functional moieties selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene, cyclohexyl, benzyl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl, wherein X, and X2 each independently comprise a carbon, nitrogen, oxygen or sulfur functionality, wherein X3 is selected from the group consisting of carboxyl, amino, gem-dialkyl, amide, ester, thioester and methylene, and wherein R comprises a group formed by reaction with a dipolarophile
99 The core structure of claim 98, wherein core structure is further attached, through a terminal reactive moiety, to another moiety selected from the group consisting of solid support unit, biomolecule, and polymer
100 A library of core compounds having the following structure
wherein Lπ comprises a moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic, aldehyde, and vinyl halide, Rb R2 and R3 are functional moieties selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene, cyclohexyl, benzyl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl, wherein X, and X2 each independently comprise a carbon, nitrogen, oxygen or sulfur functionality, wherein X3 is selected from the group consisting of carboxyl, amino, gem-dialkyl, amide, ester, thioester and methylene, and wherein R4 comprises a group formed by reaction with a dipolarophile
101 The library of claim 100, wherein each of said compounds in said library is furthei attached, through one or more reactive terminal moieties, to another moiety selected from the group consisting of solid support unit, biomolecule, and polymer
102 A core compound having the following structure
wherein Lπ comprises a moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic, aldehyde, and vinyl halide, Rb R2 and R3 are functional moieties selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene, cyclohexyl, benzyl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl, wherein X, comprises a carbon, nitrogen, oxygen or sulfur functionality, wherein X3 is selected from the group consisting of carboxyl, amino, gem-dialkyl, amide, ester, thioester and methylene, wherein A comprises a diversifiable segment unit, and wherein R4 comprises a group formed by a hydrozirconation reaction The library of claim 17, wherein each of said compounds in said library is further attached, through one or more reactive terminal moieties, to another moiety selected from the group consisting of solid support unit, biomolecule, and polymer.
103. The core compound of claim 102, wherein said compound further attached, through a terminal reactive moiety, to another moiety selected from the group consisting of solid support unit, biomolecule, and polymer.
104. A library of core compounds having the following structure:
wherein Lu comprises a moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic, aldehyde, and vinyl halide; Rb R2 and R3 are functional moieties selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene, cyclohexyl, benzyl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl; wherein X, comprises a carbon, nitrogen, oxygen or sulfur functionality; wherein X3 is selected from the group consisting of carboxyl, amino, gem-dialkyl, amide, ester, thioester and methylene; wherein A comprises a diversifiable segment unit; and wherein R4 comprises a group formed by a hydrozirconation reaction.
105. The library of claim 104, wherein each of said compounds in said library is further attached, through one or more reactive terminal moieties, to another moiety selected from the group consisting of solid support unit, biomolecule, and polymer.
106. A core compound having the following structure:
wherein Lu and L22 each comprise a moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic, aldehyde, and vinyl halide; R, and R2 are functional moieties selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene, cyclohexyl, benzyl, aryloxy. heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl; wherein X, comprises a carbon, nitrogen, oxygen or sulfur functionality; wherein X3 and X4 are each independently selected from the group consisting of carboxyl, amino, gem-dialkyl, amide, ester, thioester and methylene; and wherein A comprises a diversifiable segment unit.
107. The core compound of claim 106, wherein said compound is further attached, through a reactive terminal moiety, to another moiety selected from the group consisting of solid support unit, biomolecule, and polymer.
108. A library of core compounds having the following structure:
wherein Ln and L22 each comprise a moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic, aldehyde, and vinyl halide; R, and R2 are functional moieties selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene, cyclohexyl, benzyl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl; wherein X, comprises a carbon, nitrogen, oxygen or sulfur functionality; wherein X3 and X4 are each independently selected from the group consisting of carboxyl, amino, gem-dialkyl, amide, ester, thioester and methylene; and wherein A comprises a diversifiable segment unit.
109. The library of claim 108, wherein each of said compounds in said library is further attached, through one or more reactive terminal moieties, to another moiety selected from the group consisting of solid support unit, biomolecule. and polymer.
1 10 A coie compound having the following structure:
wherein Ln and L22 each comprise a moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic, aldehyde, and vinyl halide; and R2 are functional moieties selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene, cyclohexyl, benzyl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl; wherein X3 and X4 are each independently selected from the group consisting of carboxyl, amino, gem-dialkyl, amide, ester, thioester and methylene; wherein A, comprises a halogenated aromatic moiety; and wherein A2 comprises a diversifiable segment unit.
111. The core compound of claim 110, wherein said compound is further attached, 1 through a reactive terminal moiety, to another moiety selected from the group consisting of
2 solid support unit, biomolecule, and polymer.
-┬╗
4 1 12. A library of core compounds having the following structure:
5
7 wherein Ln and L22 each comprise a moiety selected from the group consisting of
8 hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic,
9 aldehyde, and vinyl halide; R, and R2 are functional moieties selected from the group 0 consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene, cyclohexyl, 1 benzyl, aryloxy, heteroaryl, carboxyl, carboxalkyl. carboxaryl, arylalkyl, thio and hydroxyl; 2 wherein X3 and X4 are each independently selected from the group consisting of carboxyl, 3 amino. gem-dialkyl, amide, ester, thioester and methylene; wherein A, comprises a 4 halogenated aromatic moiety; and wherein A2 comprises a diversifiable segment unit 5 6 1 13 The library of claim 112, wherein each of said compounds in said library is further 7 attached, through one or more reactive terminal moieties, to another moiety selected from 8 the group consisting of solid support unit, biomolecule, and polymer. 9 0 114. A library of synthetic transcriptional regulators comprising members from the 1 library of claims 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 15, 16, 17, 19, 20, 21, 22, 23, 24, 25, 26, or 2 27 and FK506. 3 4 115. A library of inhibitors of DNA glycosylases comprising members from the library 5 of claims 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 15, 16, 17, 19, 20, 21, 22, 23, 24, 25, 26, or 27 and 6 pyrrolidine hypoxanthine.
1 116. A library of SH2 binding compounds comprising members from the library of
2 claims 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 15, 16, 17, 19, 20, 21, 22, 23, 24, 25, 26, or 27. ~>
4 117. A method for morphing a peptide into a non-peptide compound, the method
5 comprising the steps of:
6 identifying an active sequence to be mimicked;
7 preparing a library of peptide derivatives in which each peptide has the active
8 sequence except that at least one di- or tri-peptide unit has been substituted with a library of
9 non-peptide compounds; and 0 screening the peptide derivative library to identify one or more peptide derivatives 1 within it that retain at least part of the active sequence's activity. 2 3 1 18. The method of claim 1 J 7, further comprising: 4 preparing a second library of peptide derivatives, the second library being produced 5 from the first identified peptide derivative by substituting at least a second di- or tri-peptide 6 moiety within the first derivative with a library of non-peptide compounds; and 7 screening the second peptide derivative library to identify one or more second 8 peptide derivatives that retain at least part of the active sequence's activity. 9 0 119. The method of claim 1 17, wherein the steps of preparing and screening libraries are 1 integrated until a compound including no peptide bonds but retaining at least part of the 2 active sequence's activity is produced. 3 4 5 DS1.47B71.1 6
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7903598P | 1998-03-23 | 1998-03-23 | |
US79035P | 1998-03-23 | ||
PCT/US1999/006233 WO1999048897A2 (en) | 1998-03-23 | 1999-03-22 | Synthesis of compounds and libraries of compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1066295A2 true EP1066295A2 (en) | 2001-01-10 |
Family
ID=22148010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99912805A Ceased EP1066295A2 (en) | 1998-03-23 | 1999-03-22 | Synthesis of compounds and libraries of compounds |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1066295A2 (en) |
JP (1) | JP2002507617A (en) |
CA (1) | CA2324016A1 (en) |
HU (1) | HUP0103260A3 (en) |
IL (2) | IL138647A0 (en) |
WO (1) | WO1999048897A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1297338B1 (en) * | 2000-06-05 | 2007-04-18 | Novartis Vaccines and Diagnostics, Inc. | Microarrays for performing proteomic analyses |
US7153682B2 (en) | 2000-06-05 | 2006-12-26 | Chiron Corporation | Microarrays on mirrored substrates for performing proteomic analyses |
US7148058B2 (en) | 2000-06-05 | 2006-12-12 | Chiron Corporation | Protein microarrays on mirrored surfaces for performing proteomic analyses |
JP3893030B2 (en) * | 2001-04-18 | 2007-03-14 | 独立行政法人科学技術振興機構 | Bacterial endotoxin adsorbent and screening method thereof |
IL161121A0 (en) | 2001-10-03 | 2004-08-31 | Harvard College | Copolymers for suppression of autoimmune diseases, and methods of use |
WO2006019904A1 (en) | 2004-07-14 | 2006-02-23 | University Of Utha Research Foundation | Netrin-related compositions and uses |
CA2598289C (en) | 2005-02-25 | 2016-04-12 | University Of Utah Research Foundation | Methods and compositions for promoting endothelial cell adhesion or migration |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5877278A (en) * | 1992-09-24 | 1999-03-02 | Chiron Corporation | Synthesis of N-substituted oligomers |
DK1310510T3 (en) * | 1993-05-27 | 2007-09-24 | Aventis Pharma Inc | Topologically adhered, solid phase encoded libraries |
IL106106A0 (en) * | 1993-06-22 | 1993-10-20 | Interpharm Lab Ltd | Library of polymeric molecules and its preparation |
EP0904540A1 (en) * | 1996-03-22 | 1999-03-31 | Ontogen Corporation | Methods for spatially-dispersed positionally-encoded combinatorial library synthesis |
DE19619373A1 (en) * | 1996-05-14 | 1997-11-20 | Hoechst Ag | New substance library and the resulting supramolecular complexes |
-
1999
- 1999-03-22 JP JP2000537880A patent/JP2002507617A/en active Pending
- 1999-03-22 EP EP99912805A patent/EP1066295A2/en not_active Ceased
- 1999-03-22 CA CA002324016A patent/CA2324016A1/en not_active Abandoned
- 1999-03-22 WO PCT/US1999/006233 patent/WO1999048897A2/en active IP Right Grant
- 1999-03-22 HU HU0103260A patent/HUP0103260A3/en unknown
- 1999-03-22 IL IL13864799A patent/IL138647A0/en active IP Right Grant
-
2000
- 2000-09-22 IL IL138647A patent/IL138647A/en not_active IP Right Cessation
Non-Patent Citations (1)
Title |
---|
See references of WO9948897A2 * |
Also Published As
Publication number | Publication date |
---|---|
WO1999048897B1 (en) | 2000-01-20 |
IL138647A0 (en) | 2001-10-31 |
HUP0103260A2 (en) | 2002-02-28 |
WO1999048897A3 (en) | 1999-11-11 |
HUP0103260A3 (en) | 2002-03-28 |
JP2002507617A (en) | 2002-03-12 |
WO1999048897A2 (en) | 1999-09-30 |
IL138647A (en) | 2006-10-31 |
CA2324016A1 (en) | 1999-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7183059B2 (en) | Synthesis of compounds and libraries of compounds | |
EP0777492B1 (en) | Combinatorial libraries of substrate-bound cyclic organic compounds | |
Gordon et al. | Solid phase synthesis–designer linkers for combinatorial chemistry: a review | |
Früchtel et al. | Organic chemistry on solid supports | |
Obrecht et al. | Solid-supported combinatorial and parallel synthesis of small-molecular-weight compound libraries | |
Yang et al. | Nickel-catalyzed carbodifunctionalization of N-vinylamides enables access to γ-amino acids | |
EP0734398B1 (en) | Compounds and methods | |
US7396940B2 (en) | Combinatorial library of 3-aryl-1H-indole-2-carboxylic acid | |
US5877030A (en) | Process for creating molecular diversity and novel protease inhibitors produced thereby | |
EP1066295A2 (en) | Synthesis of compounds and libraries of compounds | |
US7126006B2 (en) | Glycoluril core molecules for combinatorial libraries | |
US6416861B1 (en) | Organosilicon compounds and uses thereof | |
EP1192136B1 (en) | Oligomers and polymers of cyclic imino carboxylic acids | |
WO1998033783A1 (en) | Solid phase and combinatorial library syntheses of 3,1-benzoxazine-4-ones | |
US5773512A (en) | Compounds and methods | |
US6175020B1 (en) | Spirodiamino acid scaffold for combinatorial synthesis | |
WO1999064379A2 (en) | Biomimetic combinatorial synthesis | |
US20050089936A1 (en) | Combinatorial library of 3-aryl-1H-indole-2-carboxylic acid amides | |
AU1907401A (en) | New functionalized polymeric reagents | |
Yellol et al. | Solid-supported synthesis | |
WO1998035923A1 (en) | Process for creating molecular diversity | |
EP0985662A2 (en) | Linker binding carriers for organic synthesis, their production and use | |
US20020146684A1 (en) | One dimensional unichemo protection (UCP) in organic synthesis | |
Bartolozzi et al. | Advances in the applications of polymer-supported reagents for organic synthesis | |
Chen | Pin1 Catalytic and WW Domain Ligands |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20001023 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20070410 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20090410 |